5-MeO-MiPT    B-Antidepressant102718811

Moxy    O
(    O
slang    O
)    O
,    O
name    O
for    O
the    O
research    O
chemical    O
5-MeO-MIPT    B-Antidepressant102718811

Indantadol    B-Antidepressant102718811
(    O
CHF-3381    B-Antidepressant102718811
,    O
V-3381    B-Antidepressant102718811
)    O
is    O
a    O
drug    O
which    O
was    O
formerly    O
being    O
investigated    O
as    O
an    O
anticonvulsant    O
and    O
neuroprotective    O
and    O
is    O
now    O
under    O
development    O
for    O
the    O
treatment    O
of    O
neuropathic    O
pain    O
and    O
chronic    O
cough    O
in    O
Europe    O
by    O
Vernalis    O
and    O
Chiesi    O
.    O

Rosin    O
is    O
a    O
glycoside    O
ester    O
of    O
Cinnamyl    O
alcohol    O
and    O
a    O
constituent    O
of    O
"    O
Rhodiola    B-Antidepressant102718811
rosea    I-Antidepressant102718811
"    O
.    O

Rosarin    O
is    O
a    O
cinnamyl    O
alcohol    O
glycoside    O
isolated    O
from    O
"    O
Rhodiola    B-Antidepressant102718811
rosea    I-Antidepressant102718811
"    O
.    O

"    O
Rhodiola    B-Antidepressant102718811
rosea    I-Antidepressant102718811
"    O
,    O
the    O
golden    O
root    O
,    O
roseroot    O
or    O
Aaron    O
's    O
Rod    O
,    O
a    O
plant    O
species    O
found    O
in    O
cold    O
regions    O
of    O
the    O
world    O

Lotaustralin    O
is    O
a    O
cyanogenic    O
glucoside    O
found    O
in    O
small    O
amounts    O
in    O
Fabaceae    O
Austral    O
Trefoil    O
(    O
"    O
Lotus    O
australis    O
"    O
)    O
,    O
cassava    O
(    O
"    O
Manihot    O
esculenta    O
"    O
)    O
,    O
lima    O
bean    O
(    O
"    O
Phaseolus    O
lunatus    O
"    O
)    O
,    O
roseroot    B-Antidepressant102718811
(    O
"    O
Rhodiola    O
rosea    O
"    O
)    O
and    O
white    O
clover    O
(    O
"    O
Trifolium    O
repens    O
"    O
)    O
,    O
among    O
other    O
plants    O
.    O

Badge    O
:    O
juniper    O
,    O
or    O
roseroot    B-Antidepressant102718811

Amedalin    B-Antidepressant102718811
(    O
UK-3540    O
-    O
1    O
)    O

Flupentixol/melitracen    B-Antidepressant102718811

Initial    O
studies    O
found    O
that    O
upon    O
acute    O
and    O
repeated    O
administration    O
,    O
tianeptine    O
decreased    O
the    O
extracellular    O
levels    O
of    O
serotonin    O
in    O
rat    O
brain    O
without    O
a    O
decrease    O
in    O
serotonin    O
release    O
and    O
it    O
was    O
hence    O
called    O
a    O
"    O
(    O
selective    O
)    O
serotonin    O
reuptake    B-Antidepressant102718811
enhancer    I-Antidepressant102718811
"    O
.    O

Omiloxetine    B-Antidepressant102718811
(    O
omiloextinum    B-Antidepressant102718811
,    O
omiloxetino    B-Antidepressant102718811
INN    O
)    O
was    O
a    O
selective    O
serotonin    O
reuptake    O
inhibitor    O
drug    O
candidate    O
that    O
underwent    O
preclinical    O
development    O
by    O
the    O
Spanish    O
pharmaceutical    O
company    O
,    O
Ferrer    O
Internacional    O
,    O
until    O
2005    O
,    O
when    O
it    O
was    O
abandoned    O
.    O

Flucindole    B-Antidepressant102718811

Hydrazine    B-Antidepressant102718811
(antidepressant)    I-Antidepressant102718811

Hydrazine    B-Antidepressant102718811
(antidepressant)    I-Antidepressant102718811

The    O
beverages    O
include    O
taurine    O
,    O
caffeine    O
,    O
Siberian    B-Antidepressant102718811
Ginseng    I-Antidepressant102718811
,    O
Guarana    O
seed    O
extract    O
and    O
various    O
vitamins    O
,    O
and    O
use    O
cane    O
sugar    O
instead    O
of    O
commonly    O
used    O
high    O
fructose    O
corn    O
syrup    O
.    O

Considers    O
anti    O
-    O
inflammatory    O
properties    O
of    O
dried    O
roots    O
from    O
the    O
species    O
"    O
Angelica    O
sinensis    O
(    O
Dong    O
Quai    O
)    O
"    O
,    O
"    O
Acanthopanax    B-Antidepressant102718811
senticosus    I-Antidepressant102718811
"    O
(    O
now    O
known    O
as    O
Eleutherococcus    B-Antidepressant102718811
senticosus    I-Antidepressant102718811
,    O
or    O
Siberian    O
Ginseng    O
)    O
,    O
and    O
"    O
Scutellaria    O
baicalensis    O
(    O
Baikal    O
Skullcap    O
)    O
"    O
.    O

When    O
originally    O
introduced    O
,    O
the    O
active    O
ingredients    O
in    O
Altovis    O
were    O
green    O
tea    O
leaf    O
extract    O
(    O
provides    O
caffeine    O
)    O
,    O
cordyceps    O
extract    O
(    O
mycelium    O
)    O
,    O
Eleutherococcus    B-Antidepressant102718811
(    O
Siberian    O
ginseng    O
)    O
,    O
vinpocetine    O
(    O
from    O
vocanga    O
tree    O
seeds    O
)    O
,    O
and    O
octacosanol    O
.    O

"    O
Eleutherococcus    B-Antidepressant102718811
senticosus    I-Antidepressant102718811
"    O
(    O
Siberian    O
ginseng    O
)    O

Triazolopyridine    B-Antidepressant102718811
is    O
a    O
class    O
of    O
antidepressants    O
chemically    O
and    O
pharmacologically    O
unrelated    O
to    O
other    O
similarly    O
performing    O
antidepressants    O
;    O
clinical    O
effectiveness    O
appears    O
pharmacologically    O
similar    O
to    O
other    O
tricyclic    O
antidepressants    O
,    O
although    O
it    O
seems    O
to    O
have    O
less    O
anticholinergic    O
effects    O
.    O

Domoxin    B-Antidepressant102718811

Cimemoxin    B-Antidepressant102718811
(    O
INN    O
)    O
,    O
or    O
cyclohexylmethylhydrazine    B-Antidepressant102718811
,    O
is    O
a    O
hydrazine    O
monoamine    O
oxidase    O
inhibitor    O
(    O
MAOI    O
)    O
antidepressant    O
which    O
was    O
never    O
marketed    O
.    O

losindole    B-Antidepressant102718811
(    O
INN    O
)    O

Trazodone    O
appears    O
to    O
be    O
relatively    O
safer    O
than    O
TCAs    O
,    O
MAOIs    O
,    O
and    O
a    O
few    O
of    O
the    O
other    O
second-generation    B-Antidepressant102718811
antidepressant    I-Antidepressant102718811
in    O
overdose    O
situations    O
,    O
especially    O
when    O
it    O
is    O
the    O
only    O
agent    O
taken    O
.    O

However    O
,    O
norepinephrine    O
has    O
been    O
implicated    O
as    O
acting    O
synergistically    O
with    O
dopamine    O
when    O
actions    O
on    O
the    O
two    O
neurotransmitters    O
are    O
combined    O
(    O
e.g.    O
,    O
in    O
the    O
case    O
of    O
NDRI    B-Antidepressant102718811
)    O
to    O
produce    O
rewarding    O
effects    O
in    O
psychostimulant    O
drugs    O
of    O
abuse    O
.    O

For    O
a    O
list    O
of    O
NRIs    O
that    O
act    O
at    O
multiple    O
MATs    O
,    O
see    O
the    O
other    O
monoamine    O
reuptake    O
inhibitor    O
pages    O
such    O
as    O
NDRI    B-Antidepressant102718811
,    O
SNRI    B-Antidepressant102718811
,    O
and    O
SNDRI    O
.    O

Bupropion    B-Antidepressant102718811
(    O
Wellbutrin    O
)    O
,    O
NDRI    B-Antidepressant102718811

Methylphenidate    O
(    O
Ritalin    O
,    O
Concerta    O
)    O
,    O
a    O
norepinephrine-dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811

Norepinephrine–dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
NDRI    O
)    O

Desoxypipradrol    O
,    O
also    O
known    O
as    O
2-diphenylmethylpiperidine    O
(    O
2-DPMP    O
)    O
,    O
acts    O
as    O
a    O
norepinephrine-dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
NDRI    O
)    O
developed    O
by    O
Ciba    O
in    O
the    O
1950s    O
.    O

Norepinephrine-dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811

Hyperforin    B-Antidepressant102718811
and    O
adhyperforin    O
,    O
two    O
phloroglucinol    O
constituents    O
of    O
St    O
John    O
's    O
wort    O
,    O
are    O
TRPC6    O
receptor    O
agonists    O
and    O
,    O
consequently    O
,    O
they    O
induce    O
noncompetitive    O
reuptake    B-Antidepressant102718811
inhibition    I-Antidepressant102718811
of    O
monoamines    O
(    O
specifically    O
,    O
dopamine    B-Antidepressant102718811
,    O
norepinephrine    B-Antidepressant102718811
,    O
and    O
serotonin    O
)    O
,    O
GABA    O
,    O
and    O
glutamate    O
when    O
they    O
activate    O
this    O
ion    O
channel    O
.    O

It    O
acts    O
as    O
a    O
potent    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
,    O
with    O
fair    O
selectivity    O
over    O
the    O
serotonin    O
and    O
dopamine    O
transporters    O
,    O
and    O
also    O
behaves    O
as    O
an    O
antagonist    O
of    O
the    O
5-HT2A    O
receptor    O
.    O

=    O
=    O
Reuptake    B-Antidepressant102718811
inhibitors    I-Antidepressant102718811
=    O
=    O

Viloxazine    B-Antidepressant102718811
(    O
trade    O
names    O
Vivalan    B-Antidepressant102718811
,    O
Emovit    B-Antidepressant102718811
,    O
Vivarint    B-Antidepressant102718811
and    O
Vicilan    B-Antidepressant102718811
)    O
is    O
a    O
morpholine    O
derivative    O
and    O
is    O
a    O
selective    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
NRI    O
)    O
.    O

The    O
psychoactive    O
drug    O
cocaine    O
potently    O
inhibits    O
the    O
normal    O
reuptake    B-Antidepressant102718811
of    I-Antidepressant102718811
norepinephrine    I-Antidepressant102718811
into    O
presynaptic    O
nerve    O
terminals    O
,    O
resulting    O
in    O
an    O
increased    O
level    O
of    O
extracellular    O
norepinephrine    O
.    O

A    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
NRI    B-Antidepressant102718811
,    O
NERI    B-Antidepressant102718811
)    O
or    O
adrenergic    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
ARI    B-Antidepressant102718811
)    O
,    O
is    O
a    O
type    O
of    O
drug    O
that    O
acts    O
as    O
a    O
reuptake    B-Antidepressant102718811
inhibitor    I-Antidepressant102718811
for    O
the    O
neurotransmitters    O
norepinephrine    O
(    O
noradrenaline    O
)    O
and    O
epinephrine    O
(    O
adrenaline    O
)    O
by    O
blocking    O
the    O
action    O
of    O
the    O
norepinephrine    O
transporter    O
(    O
NET    O
)    O
.    O

The    O
drug    O
has    O
relatively    O
weak    O
effects    O
as    O
an    O
alpha-1    O
blocker    O
and    O
has    O
no    O
effects    O
as    O
a    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
,    O
so    O
is    O
associated    O
with    O
little    O
to    O
no    O
antiadrenergic    O
and    O
adrenergic    O
side    O
effects    O
.    O

Norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
NRI    O
)    O

Levonorfenfluramine    O
,    O
an    O
active    O
metabolite    O
of    O
levofenfluramine    O
,    O
is    O
also    O
a    O
fairly    O
potent    O
serotonin    O
releasing    O
agent    O
(    O
with    O
a    O
potency    O
of    O
approximately    O
1/2    O
that    O
of    O
norfenfluramine    O
and    O
1/6th    O
that    O
of    O
dexfenfluramine    O
)    O
and    O
,    O
similarly    O
to    O
dexnorfenfluramine    O
,    O
is    O
a    O
5-HT2B    O
and    O
5-HT2C    O
receptor    O
agonist    O
,    O
as    O
well    O
as    O
a    O
somewhat    O
less    O
potent    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
about    O
1/2    O
that    O
of    O
its    O
efficacy    O
as    O
a    O
serotonin    O
releaser    O
)    O
.    O

Anxious    O
or    O
irritable    O
patients    O
should    O
be    O
treated    O
with    O
SSRIs    O
or    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
,    O
and    O
the    O
ones    O
with    O
the    O
loss    O
of    O
energy    O
and    O
enjoyment    O
of    O
life    O
—    O
with    O
norepinephrine    O
and    O
dopamine    O
enhancing    O
drugs    O
.    O

Edivoxetine    B-Antidepressant102718811
(    O
INN    O
;    O
code    O
name    O
LY-2216684    B-Antidepressant102718811
)    O
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
selective    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
and    O
was    O
under    O
development    O
by    O
Eli    O
Lilly    O
for    O
attention    O
-    O
deficit    O
disorder    O
(    O
ADD    O
)    O
and    O
as    O
an    O
antidepressant    O
treatment    O
.    O

Tramadol    O
is    O
structurally    O
closer    O
to    O
venlafaxine    B-Antidepressant102718811
than    O
to    O
codeine    O
and    O
delivers    O
analgesia    O
by    O
not    O
only    O
delivering    O
"    O
opioid    O
-    O
like    O
"    O
effects    O
(    O
through    O
mild    O
agonism    O
of    O
the    O
mu    O
receptor    O
)    O
but    O
also    O
by    O
acting    O
as    O
a    O
weak    O
but    O
fast    O
-    O
acting    O
serotonin    O
releasing    O
agent    O
and    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
.    O

The    O
effects    O
of    O
serotonin    O
and    O
norepinephrine    B-Antidepressant102718811
on    O
pain    O
,    O
while    O
not    O
completely    O
understood    O
,    O
have    O
had    O
causal    O
links    O
established    O
and    O
drugs    O
in    O
the    O
SNRI    O
class    O
are    O
commonly    O
used    O
in    O
conjunction    O
with    O
opioids    O
(    O
especially    O
tapentadol    O
and    O
tramadol    O
)    O
with    O
greater    O
success    O
in    O
pain    O
relief    O
.    O

:    O
N06AA23    O
Quinupramine    B-Antidepressant102718811

Benmoxin    B-Antidepressant102718811
(    O
trade    O
names    O
Neuralex    B-Antidepressant102718811
,    O
Nerusil    B-Antidepressant102718811
)    O
,    O
also    O
known    O
as    O
mebamoxine    B-Antidepressant102718811
,    O
is    O
an    O
irreversible    O
and    O
nonselective    O
monoamine    O
oxidase    O
inhibitor    O
(    O
MAOI    O
)    O
of    O
the    O
hydrazine    O
class    O
.    O

Flibanserin    B-Antidepressant102718811

Flibanserin    B-Antidepressant102718811

Multifunctional    O
serotonin    O
agonist    O
and    O
antagonist    O
;    O
See    O
Flibanserin    B-Antidepressant102718811

maprotiline    B-Antidepressant102718811
(    O
Ludiomil    O
)    O

maprotiline    B-Antidepressant102718811
(    O
INN    O
)    O

Maprotiline    B-Antidepressant102718811
(    O
Deprilept    O
,    O
Ludiomil    O
,    O
Psymion    O
)    O

Maprotiline    B-Antidepressant102718811

7-Hydroxyamoxapine    B-Antidepressant102718811
,    O
a    O
major    O
active    O
metabolite    O
of    O
amoxapine    O
,    O
is    O
a    O
more    O
potent    O
dopamine    O
receptor    O
antagonist    O
and    O
contributes    O
to    O
its    O
neuroleptic    O
efficacy    O
,    O
whereas    O
8-hydroxyamoxapine    O
is    O
a    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
but    O
a    O
stronger    O
serotonin    O
reuptake    O
inhibitor    O
and    O
helps    O
to    O
balance    O
amoxapine    O
's    O
ratio    O
of    O
serotonin    O
to    O
norepinephrine    O
transporter    O
blockade    O
.    O

Yohimbine    B-Antidepressant102718811

Yohimbine    B-Antidepressant102718811

Yohimbine    B-Antidepressant102718811

Yohimbine    B-Antidepressant102718811

BZP    O
has    O
a    O
high    O
affinity    O
action    O
at    O
the    O
alpha2-adrenoreceptor    O
,    O
it    O
is    O
an    O
antagonist    O
at    O
the    O
receptor    O
,    O
like    O
yohimbine    B-Antidepressant102718811
,    O
which    O
inhibits    O
negative    O
feedback    O
,    O
causing    O
an    O
increase    O
in    O
released    O
noradrenaline    O
.    O

Yohimbine    B-Antidepressant102718811

Yohimbine    B-Antidepressant102718811
,    O
by    O
the    O
trade    O
name    O
"    O
Yocon    O
"    O

A    O
number    O
of    O
other    O
measures    O
have    O
slight    O
evidence    O
to    O
support    O
their    O
use    O
indomethacin    O
,    O
fluoxetine    O
,    O
dopamine    O
antagonists    O
,    O
metoclopramide    O
,    O
domperidone    O
,    O
monoamine    O
oxidase    O
inhibitors    O
with    O
tyramine    O
(    O
can    O
produce    O
severe    O
hypertension    O
)    O
,    O
oxilofrine    O
,    O
potassium    O
chloride    O
,    O
and    O
yohimbine    B-Antidepressant102718811
.    O

Caffeine    O
,    O
cocaine    O
,    O
codeine    O
and    O
nicotine    O
are    O
slightly    O
soluble    O
in    O
water    O
(    O
with    O
a    O
solubility    O
of    O
≥1g    O
/    O
L    O
)    O
,    O
whereas    O
others    O
,    O
including    O
morphine    O
and    O
yohimbine    B-Antidepressant102718811
are    O
very    O
slightly    O
water    O
-    O
soluble    O
(    O
0.1–1    O
g    O
/    O
L    O
)    O
.    O

Fenmetozole    B-Antidepressant102718811
has    O
the    O
precise    O
same    O
formula    O
,    O
albeit    O
instead    O
of    O
an    O
ortho    O
-    O
isopropyl    O
group    O
,    O
3',4'-dich    O
was    O
chosen    O
instead    O
.    O

Velvet    B-Antidepressant102718811
bean    I-Antidepressant102718811

Fava    O
beans    O
and    O
velvet    B-Antidepressant102718811
beans    I-Antidepressant102718811
are    O
natural    O
sources    O
of    O
levodopa    O
and    O
are    O
eaten    O
by    O
many    O
people    O
with    O
PD    O
;    O
their    O
intake    O
is    O
not    O
free    O
of    O
risks    O
as    O
life    O
-    O
threatening    O
adverse    O
reactions    O
have    O
been    O
described    O
,    O
such    O
as    O
the    O
neuroleptic    O
malignant    O
syndrome    O
.    O

Velvet    B-Antidepressant102718811
bean    I-Antidepressant102718811
(    O
"    O
M.    O
pruriens    O
"    O
)    O
is    O
one    O
of    O
the    O
most    O
important    O
sources    O
of    O
L    O
-    O
dopa    O
,    O
a    O
common    O
component    O
of    O
nootropics    O
(    O
"    O
smart    O
drugs    O
"    O
)    O
;    O
it    O
also    O
contains    O
serotonin    O
,    O
5-HTP    B-Antidepressant102718811
,    O
nicotine    O
,    O
and    O
some    O
decidedly    O
psychoactive    O
compounds    O
(    O
see    O
below    O
)    O
.    O

"    O
Mucuna    B-Antidepressant102718811
pruriens    I-Antidepressant102718811
"    O
(    O
L.    O
)    O
DC    O
.    O

5-MeO    O
-    O
DMT    O
,    O
one    O
of    O
the    O
psychedelic    O
tryptamines    O
found    O
in    O
velvet    B-Antidepressant102718811
bean    I-Antidepressant102718811
(    O
"    O
M.    O
pruriens    O
"    O
)    O
in    O
trace    O
quantities    O
.    O

5-MeO-DIPT    B-Antidepressant102718811

5-methoxy    O
-    O
diisopropyltryptamine    O
(5-MeO-DiPT    B-Antidepressant102718811
)    O
,    O
sometimes    O
called    O
"Foxy"    B-Antidepressant102718811
,    O
is    O
a    O
psychedelic    O
tryptamine    O
.    O

DPT    O
is    O
not    O
scheduled    O
at    O
the    O
federal    O
level    O
in    O
the    O
United    O
States    O
,    O
but    O
it    O
could    O
be    O
considered    O
an    O
analog    O
of    O
5-MeO-DiPT    B-Antidepressant102718811
,    O
DMT    O
,    O
or    O
DET    O
,    O
in    O
which    O
case    O
purchase    O
,    O
sale    O
,    O
or    O
possession    O
could    O
be    O
prosecuted    O
under    O
the    O
Federal    O
Analog    O
Act    O
.    O

Metfendrazine    B-Antidepressant102718811
(    O
HM-11    B-Antidepressant102718811
,    O
MO-482    B-Antidepressant102718811
)    O
,    O
also    O
known    O
as    O
methphendrazine    B-Antidepressant102718811
,    O
is    O
an    O
irreversible    O
and    O
nonselective    O
monoamine    O
oxidase    O
inhibitor    O
(    O
MAOI    O
)    O
of    O
the    O
hydrazine    O
chemical    O
class    O
.    O

Talopram    B-Antidepressant102718811

#    O
PMA    B-Antidepressant102718811
&    O
PMMA    B-Antidepressant102718811

Modified    O
"    O
designer    O
amphetamines    O
"    O
gained    O
popularity    O
since    O
the    O
1960s    O
,    O
such    O
as    O
MDA    O
and    O
PMA    B-Antidepressant102718811
.    O

On    O
7    O
June    O
,    O
the    O
PNP    O
Crime    O
Laboratory    O
confirmed    O
that    O
the    O
amphetamine    O
-    O
based    O
metabolites    O
"para"-Methoxyamphetamine    B-Antidepressant102718811
and    O
methylenedioxyamphetamine    O
were    O
found    O
on    O
the    O
bodies    O
of    O
Migawa    O
and    O
Miller    O
,    O
in    O
addition    O
to    O
traces    O
of    O
methylenedioxycathinone    O
found    O
on    O
Migawa    O
.    O

After    O
consuming    O
a    O
PMA    B-Antidepressant102718811
-    O
containing    O
ecstasy    O
tablet    O
,    O
Ickarus    O
goes    O
into    O
a    O
drug    O
-    O
induced    O
psychosis    O
,    O
eventually    O
finding    O
himself    O
naked    O
in    O
a    O
Berlin    O
hotel    O
where    O
his    O
antics    O
attract    O
the    O
attention    O
of    O
the    O
hotel    O
staff    O
.    O

In    O
a    O
recent    O
study    O
,    O
researchers    O
identified    O
thirty    O
-    O
one    O
alkaloids    O
in    O
samples    O
of    O
plant    O
foliage    O
,    O
including    O
trace    O
amounts    O
of    O
four    O
amphetamines    O
previously    O
known    O
only    O
from    O
laboratory    O
synthesis    O
:    O
amphetamine    O
,    O
methamphetamine    O
,    O
"    O
para    O
"-    O
hydroxyamphetamine    O
and    O
"para"-methoxyamphetamine    B-Antidepressant102718811
.    O

JNJ-26489112    B-Antidepressant102718811
is    O
an    O
anticonvulsant    O
drug    O
being    O
developed    O
by    O
Johnson    O
&    O
Johnson    O
for    O
the    O
treatment    O
of    O
epilepsy    O
.    O

Hyperforin    B-Antidepressant102718811
and    O
adhyperforin    O
,    O
two    O
phloroglucinol    O
constituents    O
of    O
St    O
John    O
's    O
wort    O
,    O
are    O
TRPC6    O
receptor    O
agonists    O
and    O
,    O
consequently    O
,    O
they    O
induce    O
noncompetitive    O
reuptake    B-Antidepressant102718811
inhibition    I-Antidepressant102718811
of    O
monoamines    O
(    O
specifically    O
,    O
dopamine    B-Antidepressant102718811
,    O
norepinephrine    B-Antidepressant102718811
,    O
and    O
serotonin    O
)    O
,    O
GABA    O
,    O
and    O
glutamate    O
when    O
they    O
activate    O
this    O
ion    O
channel    O
.    O

These    O
compounds    O
are    O
inhibitor    B-Antidepressant102718811
of    O
the    O
reuptake    O
of    O
serotonin    O
,    O
norepinephrine    O
,    O
dopamine    O
,    O
γ-aminobutyric    O
acid    O
,    O
and    O
glutamate    O
,    O
and    O
they    O
are    O
reported    O
to    O
exert    O
these    O
effects    O
by    O
binding    O
to    O
and    O
activating    O
TRPC6    O
.    O

Tuaminoheptane    O
has    O
been    O
found    O
to    O
act    O
as    O
a    O
reuptake    B-Antidepressant102718811
inhibitor    I-Antidepressant102718811
and    O
releasing    O
agent    O
of    O
norepinephrine    O
,    O
which    O
may    O
underlie    O
its    O
decongestant    O
and    O
stimulant    O
effects    O
.    O

In    O
animal    O
studies    O
,    O
5-APDB    O
's    O
effects    O
generalize    O
most    O
closely    O
to    O
non    O
-    O
stimulant    O
MDMA    O
analogues    O
such    O
as    O
MBDB    O
and    O
MMAI    O
,    O
while    O
producing    O
no    O
substitution    O
for    O
LSD    O
or    O
amphetamine    O
.    O
"    O
In    O
vitro    O
"    O
studies    O
show    O
that    O
5-APDB    O
acts    O
as    O
a    O
highly    O
selective    O
serotonin    O
releasing    O
agent    O
(    O
SSRA    O
)    O
,    O
with    O
IC50    O
values    O
of    O
130    O
nM    O
,    O
7,089    O
nM    O
,    O
and    O
3,238    O
nM    O
for    O
inhibiting    B-Antidepressant102718811
the    O
reuptake    O
of    O
serotonin    O
,    O
dopamine    O
,    O
and    O
norepinephrine    O
,    O
respectively    O
.    O

A    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
NRI    B-Antidepressant102718811
,    O
NERI    B-Antidepressant102718811
)    O
or    O
adrenergic    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
ARI    B-Antidepressant102718811
)    O
,    O
is    O
a    O
type    O
of    O
drug    O
that    O
acts    O
as    O
a    O
reuptake    B-Antidepressant102718811
inhibitor    I-Antidepressant102718811
for    O
the    O
neurotransmitters    O
norepinephrine    O
(    O
noradrenaline    O
)    O
and    O
epinephrine    O
(    O
adrenaline    O
)    O
by    O
blocking    O
the    O
action    O
of    O
the    O
norepinephrine    O
transporter    O
(    O
NET    O
)    O
.    O

Whereas    O
the    O
latter    O
directly    O
act    O
on    O
the    O
dopamine    O
transporter    O
to    O
inhibit    B-Antidepressant102718811
the    O
reuptake    O
and/or    O
induce    O
the    O
release    O
of    O
dopamine    O
,    O
bromantane    O
instead    O
acts    O
via    O
indirect    O
genomic    O
mechanisms    O
to    O
produce    O
a    O
rapid    O
,    O
pronounced    O
,    O
and    O
long    O
-    O
lasting    O
upregulation    O
in    O
a    O
variety    O
of    O
brain    O
regions    O
of    O
the    O
expression    O
of    O
tyrosine    O
hydroxylase    O
(    O
TH    O
)    O
and    O
aromatic    O
L    O
-    O
amino    O
acid    O
decarboxylase    O
(    O
AAAD    O
)    O
(    O
also    O
known    O
as    O
DOPA    O
decarboxylase    O
)    O
,    O
key    O
enzymes    O
in    O
the    O
dopamine    O
biosynthesis    O
pathway    O
.    O

Lofepramine    O
is    O
a    O
strong    O
inhibitor    B-Antidepressant102718811
of    O
norepinephrine    O
reuptake    O
and    O
a    O
moderate    O
inhibitor    O
of    O
serotonin    O
reuptake    O
.    O

It    O
was    O
thought    O
that    O
TCAs    O
work    O
by    O
inhibiting    B-Antidepressant102718811
the    O
reuptake    O
of    O
the    O
neurotransmitters    O
norepinephrine    O
and    O
serotonin    O
by    O
neurons    O
.    O

Iprindole    O
is    O
unique    O
compared    O
to    O
most    O
other    O
TCAs    O
in    O
that    O
it    O
is    O
a    O
very    O
weak    O
and    O
negligible    O
inhibitor    B-Antidepressant102718811
of    O
the    O
reuptake    O
of    O
serotonin    O
and    O
norepinephrine    O
and    O
appears    O
to    O
act    O
instead    O
as    O
a    O
selective    O
albeit    O
weak    O
antagonist    O
of    O
5-HT2    O
receptors    O
;    O
hence    O
its    O
classification    O
by    O
some    O
as    O
"    O
second    O
-    O
generation    O
"    O
.    O

It    O
is    O
presumed    O
to    O
act    O
as    O
an    O
inhibitor    B-Antidepressant102718811
or    O
antagonist    O
/    O
inverse    O
agonist    O
of    O
all    O
sites    O
.    O

Unlike    O
other    O
TCAs    O
,    O
opipramol    O
does    O
not    O
inhibit    B-Antidepressant102718811
the    O
reuptake    O
of    O
serotonin    O
or    O
norepinephrine    O
.    O

A    O
monoamine    O
reuptake    O
inhibitor    O
(    O
MRI    O
)    O
is    O
a    O
drug    O
that    O
acts    O
as    O
a    O
reuptake    B-Antidepressant102718811
inhibitor    I-Antidepressant102718811
of    O
one    O
or    O
more    O
of    O
the    O
three    O
major    O
monoamine    O
neurotransmitters    O
serotonin    O
,    O
norepinephrine    O
,    O
and    O
dopamine    O
by    O
blocking    O
the    O
action    O
of    O
one    O
or    O
more    O
of    O
the    O
respective    O
monoamine    O
transporters    O
(    O
MATs    O
)    O
,    O
which    O
include    O
the    O
serotonin    O
transporter    O
(    O
SERT    O
)    O
,    O
norepinephrine    O
transporter    O
(    O
NET    O
)    O
,    O
and    O
dopamine    O
transporter    O
(    O
DAT    O
)    O
.    O

CI-966    O
(    O
developmental    O
code    O
name    O
)    O
is    O
a    O
central    O
nervous    O
system    O
depressant    O
acting    O
as    O
a    O
GABA    O
reuptake    O
inhibitor    O
,    O
specifically    O
a    O
highly    O
potent    O
and    O
selective    O
blocker    B-Antidepressant102718811
of    O
the    O
GABA    O
transporter    O
1    O
(    O
GAT-1    O
)    O
(    O
IC50    O
=    O
0.26    O
µM    O
)    O
,    O
and    O
hence    O
indirect    O
and    O
non    O
-    O
selective    O
GABA    O
receptor    O
full    O
agonist    O
.    O

Unlike    O
many    O
other    O
antidepressants    O
,    O
it    O
does    O
not    O
inhibit    B-Antidepressant102718811
the    O
reuptake    O
of    O
serotonin    O
,    O
norepinephrine    O
,    O
or    O
dopamine    O
,    O
nor    O
does    O
it    O
inhibit    O
monoamine    O
oxidase    O
.    O

Further    O
experimental    O
modifications    O
of    O
the    O
chemical    O
structure    O
of    O
lometraline    O
resulted    O
in    O
the    O
discovery    O
of    O
tametraline    O
,    O
a    O
potent    O
inhibitor    B-Antidepressant102718811
of    O
the    O
reuptake    O
of    O
dopamine    O
and    O
norepinephrine    O
,    O
which    O
in    O
turn    O
led    O
to    O
the    O
discovery    O
of    O
the    O
now    O
widely    O
popular    O
antidepressant    O
sertraline    O
,    O
a    O
selective    O
serotonin    O
reuptake    O
inhibitor    O
(    O
SSRI    O
)    O
.    O

Zometapine    B-Antidepressant102718811
(    O
CI-781    B-Antidepressant102718811
)    O
is    O
an    O
antidepressant    O
drug    O
which    O
is    O
a    O
pyrazolodiazepine    O
derivative    O
.    O

In    O
the    O
1950s    O
the    O
first    O
modern    O
antipsychotic    O
and    O
antidepressant    O
drugs    O
were    O
developed    O
:    O
chlorpromazine    O
(    O
Thorazine    O
)    O
,    O
which    O
was    O
one    O
of    O
the    O
first    O
widely    O
used    O
antipsychotic    O
medications    O
to    O
be    O
developed    O
,    O
and    O
iproniazid    B-Antidepressant102718811
,    O
which    O
was    O
one    O
of    O
the    O
first    O
antidepressants    O
developed    O
.    O

iproniazid    B-Antidepressant102718811
(    O
INN    O
)    O

Following    O
the    O
discovery    O
that    O
the    O
tuberculosis    O
(    O
TB    O
)    O
drug    O
iproniazid    B-Antidepressant102718811
elevated    O
the    O
mood    O
of    O
people    O
taking    O
it    O
for    O
TB    O
,    O
and    O
the    O
subsequent    O
discovery    O
that    O
the    O
effect    O
was    O
likely    O
due    O
to    O
inhibition    O
of    O
MAO    O
,    O
many    O
people    O
and    O
companies    O
started    O
trying    O
to    O
discover    O
MAO    O
inhibitors    O
to    O
use    O
as    O
antidepressants    O
.    O

Upon    O
the    O
discovery    O
that    O
the    O
MAO    O
inhibitor    O
iproniazid    B-Antidepressant102718811
resulted    O
in    O
mood    O
elevation    O
,    O
and    O
thus    O
could    O
be    O
used    O
as    O
an    O
effective    O
anti    O
-    O
depressant    O
,    O
there    O
was    O
a    O
marked    O
increase    O
in    O
pharmacological    O
research    O
on    O
drugs    O
regulating    O
monoamine    O
activity    O
.    O

Daledalin    B-Antidepressant102718811
(    O
UK-3557    O
-    O
15    O
)    O

Many    O
others    O
,    O
including    O
benmoxin    B-Antidepressant102718811
(    O
Neuralex    O
)    O
,    O
iproclozide    O
(    O
Sursum    O
)    O
,    O
iproniazid    B-Antidepressant102718811
(    O
Marsilid    O
)    O
,    O
mebanazine    B-Antidepressant102718811
(    O
Actomol    O
)    O
,    O
nialamide    O
(    O
Niamid    O
)    O
,    O
octamoxin    B-Antidepressant102718811
(    O
Ximaol    O
)    O
,    O
pheniprazine    B-Antidepressant102718811
(    O
Catron    O
)    O
,    O
phenoxypropazine    B-Antidepressant102718811
(    O
Drazine    O
)    O
,    O
pivhydrazine    B-Antidepressant102718811
(    O
Tersavid    O
)    O
,    O
and    O
safrazine    B-Antidepressant102718811
(    O
Safra    O
)    O
were    O
used    O
as    O
antidepressants    O
in    O
the    O
past    O
,    O
but    O
have    O
since    O
been    O
discontinued    O
.    O

Procyanidin    O
B8    O
is    O
a    O
catechin    B-Antidepressant102718811
epicatechin    B-Antidepressant102718811
dimer    O
.    O

It    O
is    O
an    O
epicatechin    B-Antidepressant102718811
catechin    B-Antidepressant102718811
dimer    O
found    O
in    O
"    O
Rhododendron    O
spiciferum    O
"    O
,    O
in    O
peanut    O
skins    O
and    O
in    O
"    O
Ecdysanthera    O
utilis    O
"    O
.    O

"    O
U.    O
guianensis    O
"    O
contains    O
many    O
phytochemicals    O
(    O
(    O
epicatechin    B-Antidepressant102718811
,    O
alkaloid    O
,    O
beta    O
-    O
Sitosterol    O
,    O
campesterol    O
,    O
campherol    O
,    O
catechol    O
,    O
catechutannic    O
acid    O
,    O
chlorogenic    O
acid    O
,    O
ellagic    O
acid    O
,    O
gallic    O
acid    O
,    O
hyperin    O
,    O
oleanolic    O
acid    O
,    O
rutin    O
,    O
stigmasterol    O
,    O
ursolic    O
acid    O
)    O
and    O
proanthocyanidin    O
B1    O
and    O
proanthocyanidin    O
B2    O
,    O
B    O
type    O
proanthocyanidins    O
,    O
in    O
the    O
root    O
.    O

File:(–    O
)    O
-Epicatechin.svg|(–    O
)    O
Epicatechin    B-Antidepressant102718811

Polyphenols    O
found    O
in    O
green    O
tea    O
include    O
but    O
are    O
not    O
limited    O
to    O
epigallocatechin    O
gallate    O
(    O
EGCG    O
)    O
,    O
epigallocatechin    O
,    O
epicatechin    O
gallate    O
,    O
and    O
epicatechin    B-Antidepressant102718811
;    O
flavanols    O
such    O
as    O
kaempferol    O
,    O
quercetin    O
,    O
and    O
myricitin    O
are    O
also    O
found    O
in    O
green    O
tea    O
.    O

Catechin    B-Antidepressant102718811

These    O
substrates    O
include    O
monochlorophenols    O
,    O
dichlorophenols    O
,    O
and    O
more    O
complex    O
species    O
such    O
as    O
the    O
pesticide    O
2,4,5-T.    O
Hydroxyquinol    O
commonly    O
occurs    O
in    O
nature    O
as    O
a    O
biodegradation    O
product    O
of    O
catechin    B-Antidepressant102718811
,    O
a    O
natural    O
phenol    O
found    O
in    O
plants    O
such    O
as    O
"    O
Bradyrhizobium    O
japonicum    O
"    O
.    O

"    O
B.    O
japonicum    O
"    O
is    O
able    O
to    O
degrade    O
catechin    B-Antidepressant102718811
with    O
formation    O
of    O
phloroglucinol    O
carboxylic    O
acid    O
,    O
further    O
decarboxylated    O
to    O
phloroglucinol    O
,    O
which    O
is    O
dehydroxylated    O
to    O
resorcinol    O
and    O
hydroxyquinol    O
.    O

"    O
Diaporthe    O
"    O
species    O
have    O
been    O
shown    O
to    O
transform    O
the    O
infection    O
-    O
inhibiting    O
factors    O
(    O
+    O
)    O
catechin    B-Antidepressant102718811
and    O
(    O
−)-epicatechin    O
into    O
the    O
3,4-cis    O
-    O
dihydroxyflavan    O
derivatives    O

Leucocyanidin    O
reductase    O
(    O
LCR    O
)    O
uses    O
2,3-trans-3,4-cis    O
-    O
leucocyanidin    O
to    O
produce    O
(    O
+    O
)    O
catechin    B-Antidepressant102718811
and    O
is    O
the    O
first    O
enzyme    O
in    O
the    O
proanthocyanidins    O
(    O
PA)-specific    O
pathway    O
.    O

"    O
C.    O
cupreum    O
"    O
is    O
able    O
to    O
degradae    O
catechin    B-Antidepressant102718811
.    O

The    O
chemical    O
compounds    O
oxyresveratrol    O
,    O
(    O
+    O
)    O
catechin    B-Antidepressant102718811
,    O
afzelechin-3-O    O
-    O
alpha    O
-    O
L    O
-    O
rhamnopyranoside    O
,    O
(    O
−)-epiafzelechin    O
,    O
dihydromorin    O
,    O
epiafzelechin-(4beta→8)-epicatechin    O
,    O
dadahol    O
A    O
and    O
dadahol    O
B    O
,    O
resveratrol    O
,    O
steppogenin    O
,    O
moracin    O
M    O
,    O
isogemichalcone    O
B    O
,    O
gemichalcone    O
B    O
,    O
norartocarpetin    O
and    O
engeletin    O
can    O
be    O
found    O
in    O
"    O
A.    O
dadah    O
"    O
.    O

B    O
-    O
type    O
procyanidin    O
(    O
catechin    B-Antidepressant102718811
dimer    O
)    O
can    O
be    O
converted    O
to    O
A    O
-    O
type    O
procyanidin    O
by    O
radical    O
oxidation    O
.    O

Bergenin    O
,    O
catechin    B-Antidepressant102718811
,    O
gallic    O
acid    O
,    O
gallicin    O
,    O
catechin-7-O    O
-    O
glucoside    O
and    O
β-sitosterol    O
can    O
be    O
found    O
in    O
"    O
B.    O
ciliata    O
"    O
.    O

The    O
catechu    O
extract    O
from    O
"    O
A.    O
catechu    O
"    O
figures    O
in    O
the    O
history    O
of    O
chemistry    O
in    O
giving    O
its    O
name    O
to    O
the    O
catechin    B-Antidepressant102718811
,    O
catechol    O
,    O
and    O
catecholamine    O
chemical    O
families    O
ultimately    O
derived    O
from    O
it    O
.    O

Through    O
derivatives    O
of    O
the    O
flavanols    O
in    O
its    O
extracts    O
,    O
the    O
species    O
has    O
lent    O
its    O
name    O
to    O
the    O
important    O
catechin    B-Antidepressant102718811
,    O
catechols    O
and    O
catecholamines    O
of    O
chemistry    O
and    O
biology    O
.    O

Catechin    B-Antidepressant102718811

Adatanserin    B-Antidepressant102718811

Naluzotan    B-Antidepressant102718811
—    O
antidepressant    O

These    O
actions    O
appear    O
to    O
confer    O
a    O
profile    O
similar    O
to    O
that    O
of    O
iprindole    B-Antidepressant102718811
and    O
trimipramine    O
with    O
serotonin    O
-    O
blocking    O
effects    O
as    O
the    O
apparent    O
predominant    O
mediator    O
of    O
mood    O
-    O
lifting    O
efficacy    O
.    O

Iprindole    B-Antidepressant102718811
,    O
sold    O
under    O
the    O
brand    O
names    O
Prondol    B-Antidepressant102718811
,    O
Galatur    B-Antidepressant102718811
,    O
and    O
Tertran    B-Antidepressant102718811
,    O
is    O
an    O
atypical    O
tricyclic    O
antidepressant    O
(    O
TCA    O
)    O
that    O
has    O
been    O
used    O
in    O
the    O
United    O
Kingdom    O
and    O
Ireland    O
for    O
the    O
treatment    O
of    O
depression    O
but    O
appears    O
to    O
no    O
longer    O
be    O
marketed    O
.    O

Many    O
others    O
,    O
including    O
benmoxin    B-Antidepressant102718811
(    O
Neuralex    O
)    O
,    O
iproclozide    O
(    O
Sursum    O
)    O
,    O
iproniazid    B-Antidepressant102718811
(    O
Marsilid    O
)    O
,    O
mebanazine    B-Antidepressant102718811
(    O
Actomol    O
)    O
,    O
nialamide    O
(    O
Niamid    O
)    O
,    O
octamoxin    B-Antidepressant102718811
(    O
Ximaol    O
)    O
,    O
pheniprazine    B-Antidepressant102718811
(    O
Catron    O
)    O
,    O
phenoxypropazine    B-Antidepressant102718811
(    O
Drazine    O
)    O
,    O
pivhydrazine    B-Antidepressant102718811
(    O
Tersavid    O
)    O
,    O
and    O
safrazine    B-Antidepressant102718811
(    O
Safra    O
)    O
were    O
used    O
as    O
antidepressants    O
in    O
the    O
past    O
,    O
but    O
have    O
since    O
been    O
discontinued    O
.    O

2C-T-21    B-Antidepressant102718811

Fluotracen    B-Antidepressant102718811
(    O
SKF-28,175    B-Antidepressant102718811
)    O
is    O
a    O
tricyclic    O
drug    O
which    O
possesses    O
dual    O
antidepressant    O
and    O
antipsychotic    O
activity    O
.    O

Tetrindole    B-Antidepressant102718811

2008    O
-    O
sOtToVuOtO    O
GeNeRaZiOnAlE    O
-    O
"    O
dARI    B-Antidepressant102718811
"    O

2009    O
-    O
sOtToVuOtO    O
D    O
-    O
Version    O
-    O
"    O
dARI    B-Antidepressant102718811
"    O

2010    O
-    O
In    O
Testa    O
-    O
"    O
dARI    B-Antidepressant102718811
"    O

It    O
has    O
been    O
found    O
to    O
act    O
as    O
a    O
selective    O
dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
,    O
and    O
is    O
less    O
potent    O
and    O
slower    O
-    O
acting    O
but    O
longer    O
-    O
lasting    O
than    O
dextroamphetamine    O
.    O

It    O
is    O
similar    O
to    O
nocaine    O
in    O
chemical    O
structure    O
,    O
and    O
has    O
two    O
and    O
a    O
half    O
times    O
more    O
activity    O
than    O
cocaine    O
as    O
a    O
dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
.    O

The    O
most    O
common    O
causative    O
agents    O
are    O
substituted    O
amphetamines    O
and    O
dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
such    O
as    O
cocaine    O
and    O
methylphenidate    O
.    O

Safinamide    O
also    O
inhibits    O
glutamate    O
release    O
and    O
dopamine    B-Antidepressant102718811
and    O
serotonin    O
reuptake    O
.    O

Additionally    O
,    O
many    O
drugs    O
of    O
abuse    O
such    O
as    O
cocaine    O
and    O
methylphenidate    O
possess    O
NRI    O
activity    O
,    O
though    O
it    O
is    O
important    O
to    O
mention    O
that    O
NRIs    O
without    O
combined    O
dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
DRI    O
)    O
properties    O
are    O
not    O
significantly    O
rewarding    O
and    O
hence    O
are    O
considered    O
to    O
have    O
a    O
negligible    O
abuse    O
potential    O
.    O

Unlike    O
others    O
in    O
its    O
series    O
&    O
traditional    O
DRI    B-Antidepressant102718811
ligands    O
,    O
it    O
inhibits    O
the    O
release    O
of    O
dopamine    O
in    O
addition    O
to    O
inhibiting    O
the    O
reuptake    O
of    O
released    O
dopamine    O
back    O
into    O
the    O
transporter    O
.    O

DBL-583    O
is    O
a    O
selective    O
dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
of    O
the    O
piperazine    O
chemical    O
class    O
.    O

Dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
DRI    O
)    O

Rimcazole    O
is    O
an    O
antagonist    O
of    O
the    O
sigma    O
receptor    O
as    O
well    O
as    O
a    O
dopamine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
.    O

Mirtazapine    B-Antidepressant102718811
(    O
Remeron    O
)    O
,    O
NaSSA    O

It    O
is    O
not    O
uncommon    O
for    O
SSRIs    O
to    O
cause    O
or    O
worsen    O
insomnia    O
;    O
the    O
sedating    O
noradrenergic    O
and    O
specific    O
serotonergic    O
antidepressant    O
(    O
NaSSA    O
)    O
antidepressant    O
mirtazapine    B-Antidepressant102718811
(    O
Zispin    O
,    O
Remeron    O
)    O
can    O
be    O
used    O
in    O
such    O
cases    O
.    O

He    O
was    O
prescribed    O
the    O
antidepressants    O
Zoloft    O
and    O
later    O
Avanza    B-Antidepressant102718811
.    O

Hence    O
,    O
trazodone    O
does    O
not    O
have    O
similar    O
properties    O
to    O
selective    O
serotonin    O
reuptake    O
inhibitors    O
(    O
SSRIs    O
)    O
and    O
is    O
not    O
particularly    O
associated    O
with    O
increased    O
appetite    O
and    O
weight    O
gain    O
,    O
unlike    O
other    O
5-HT2C    O
antagonists    O
like    O
mirtazapine    B-Antidepressant102718811
.    O

In    O
contrast    O
to    O
older    O
sedating    O
drugs    O
acting    O
on    O
5-HT2A    O
receptors    O
(    O
e.g.    O
,    O
mirtazapine    B-Antidepressant102718811
,    O
clozapine    O
,    O
risperidone    O
)    O
,    O
eplivanserin    O
has    O
practically    O
no    O
affinity    O
to    O
dopamine    O
,    O
histamine    O
and    O
adrenergic    O
receptors    O
.    O

Mirtazapine    B-Antidepressant102718811
,    O
sold    O
under    O
the    O
brand    O
name    O
Remeron    B-Antidepressant102718811
among    O
others    O
,    O
is    O
an    O
atypical    O
antidepressant    O
which    O
is    O
used    O
primarily    O
in    O
the    O
treatment    O
of    O
depression    O
.    O

On    O
the    O
psychiatric    O
front    O
researchers    O
at    O
Newhouse    O
supported    O
the    O
development    O
of    O
mirtazepine    B-Antidepressant102718811
,    O
a    O
novel    O
tetracyclic    B-Antidepressant102718811
anti    O
-    O
depressant    O
which    O
has    O
become    O
widely    O
prescribed    O
throughout    O
the    O
world    O
.    O

Commonly    O
used    O
ones    O
are    O
venlafaxine    B-Antidepressant102718811
,    O
nefazadone    O
,    O
bupropion    B-Antidepressant102718811
,    O
mirtazapine    B-Antidepressant102718811
and    O
trazodone    O
.    O

In    O
level    O
three    O
,    O
patients    O
were    O
offered    O
the    O
addition    O
of    O
lithium    O
or    O
triiodothyronine    O
(    O
a    O
thyroid    O
hormone    O
)    O
to    O
their    O
antidepressant    O
,    O
or    O
a    O
switch    O
to    O
another    O
antidepressant    O
(    O
mirtazapine    B-Antidepressant102718811
or    O
nortriptyline    O
)    O
.    O

Level    O
four    O
consisted    O
of    O
the    O
monoamine    O
oxidase    O
inhibitor    O
tranylcypromine    O
or    O
a    O
combination    O
of    O
venlafaxine    B-Antidepressant102718811
and    O
mirtazapine    B-Antidepressant102718811
.    O

Mirtazapine    B-Antidepressant102718811

California    B-Antidepressant102718811
rocket    I-Antidepressant102718811
fuel    I-Antidepressant102718811

:    O
N06AA03    O
Imipramine    B-Antidepressant102718811
oxide    I-Antidepressant102718811

Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
is    O
an    O
essential    O
nutrient    O
,    O
usually    O
ingested    O
as    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
.    O

The    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
-    O
rich    O
fruit    O
are    O
1–3    O
cm    O
in    O
diameter    O
and    O
yellow    O
in    O
color    O
when    O
fully    O
ripe    O
.    O

Ascorbic    B-Antidepressant102718811
Acid    I-Antidepressant102718811
15.5    O
mg    O

Ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
may    O
be    O
protective    O
against    O
CIN    O
,    O
according    O
to    O
a    O
systematic    O
review    O
of    O
randomized    O
controlled    O
trials    O
.    O

Contains    O
alkaloids    O
,    O
carotene    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
proteins    O
.    O

Coenzyme    O
Q    O
and    O
vitamin    O
supplements    O
,    O
typically    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
vitamin    O
E    O
,    O
and    O
other    O
antioxidant    O
therapies    O
have    O
been    O
suggested    O
to    O
treat    O
heroin    O
-    O
induced    O
leukoencephalopathy    O
patients    O
.    O

The    O
succulent    O
leaves    O
are    O
high    O
in    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
were    O
used    O
by    O
sailors    O
in    O
the    O
past    O
as    O
a    O
scurvy    O
preventative    O
.    O

Its    O
leaves    O
have    O
a    O
salty    O
acid    O
taste    O
and    O
are    O
high    O
in    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
so    O
were    O
used    O
by    O
sailors    O
to    O
prevent    O
scurvy    O
.    O

Ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811

GLUT1    O
is    O
also    O
a    O
major    O
receptor    O
for    O
uptake    O
of    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
as    O
well    O
as    O
glucose    O
,    O
especially    O
in    O
non    O
vitamin    O
C    O
producing    O
mammals    O
as    O
part    O
of    O
an    O
adaptation    O
to    O
compensate    O
by    O
participating    O
in    O
a    O
Vitamin    O
C    O
recycling    O
process    O
.    O

Typical    O
of    O
leaf    O
vegetables    O
,    O
Malabar    O
spinach    O
is    O
high    O
in    O
vitamin    O
A    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
iron    O
,    O
and    O
calcium    O
.    O

Vitamin    O
C    O
(    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
)    O
is    O
also    O
a    O
required    O
cofactor    O
for    O
the    O
Dopamine    O
beta    O
hydroxylase    O
enzyme    O
.    O

Acetaminophen    O
,    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
,    O
heroin    O
,    O
lactose    O
,    O
mannitol    O
,    O
morphine    O
,    O
and    O
sucrose    O
all    O
cause    O
an    O
instant    O
colour    O
change    O
to    O
purple    O
,    O
as    O
do    O
other    O
compounds    O
with    O
phenol    O
and    O
hydroxyl    O
groups    O
.    O

In    O
2008    O
,    O
the    O
company    O
introduced    O
its    O
next    O
brand    O
extension    O
,    O
five    O
flavors    O
of    O
a    O
soda    O
supplemented    O
with    O
30%    O
USRDA    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
10%    O
vitamin    O
B6    O
and    O
niacin    O
.    O

UDP    O
glucuronic    O
acid    O
is    O
a    O
sugar    O
used    O
in    O
the    O
creation    O
of    O
polysaccharides    O
and    O
is    O
an    O
intermediate    O
in    O
the    O
biosynthesis    O
of    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
(    O
except    O
in    O
primates    O
and    O
guinea    O
pigs    O
)    O
.    O

Forced    O
acid    O
diuresis    O
(    O
e.g.    O
,    O
with    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
)    O
will    O
increase    O
methamphetamine    O
excretion    O
but    O
is    O
not    O
recommended    O
as    O
it    O
may    O
increase    O
the    O
risk    O
of    O
aggravating    O
acidosis    O
,    O
or    O
cause    O
seizures    O
or    O
rhabdomyolysis    O
.    O

These    O
are    O
often    O
the    O
three    O
vitamins    O
,    O
vitamin    O
A    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
vitamin    O
E    O
and    O
polyphenol    O
antioxidants    O
.    O

Other    O
organic    O
compounds    O
produced    O
with    O
hydrochloric    O
acid    O
include    O
bisphenol    O
A    O
for    O
polycarbonate    O
,    O
activated    O
carbon    O
,    O
and    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
,    O
as    O
well    O
as    O
numerous    O
pharmaceutical    O
products    O
.    O

The    O
commercial    O
production    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
(    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
)    O
often    O
begins    O
with    O
sorbose    O
.    O

Other    O
supplements    O
may    O
also    O
be    O
needed    O
,    O
including    O
:    O
cobalamin    O
,    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
,    O
folic    O
acid    O
,    O
nicotinamide    O
,    O
zinc    O
,    O
phosphorus    O
(    O
dicalcium    O
phosphate    O
)    O
and    O
in    O
some    O
cases    O
taurine    O
,    O
especially    O
suitable    O
when    O
there    O
cardiocirculatory    O
impairment    O
.    O

Many    O
multivitamin    O
"    O
formulas    O
"    O
contain    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
B1    O
,    O
B2    O
,    O
B3    O
,    O
B5    O
,    O
B6    O
,    O
B9    O
,    O
B12    O
,    O
biotin    O
,    O
A    O
,    O
E    O
,    O
D2    O
(    O
or    O
D3    O
)    O
,    O
K    O
,    O
potassium    O
,    O
iodine    O
,    O
selenium    O
,    O
borate    O
,    O
zinc    O
,    O
calcium    O
,    O
magnesium    O
,    O
manganese    O
,    O
molybdenum    O
,    O
betacarotene    O
,    O
and/or    O
iron    O
.    O

Rani    O
Juice    O
has    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
other    O
things    O
like    O
protein    O
and    O
calcium    O
.    O

Full    O
skin    O
care    O
ranges    O
(    O
including    O
Tea    O
tree    O
,    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
Vitamin    O
E    O
,    O
Aloe    O
vera    O
and    O
Seaweed    O
)    O

Redoxon    O
is    O
the    O
name    O
of    O
the    O
first    O
artificially    O
synthesized    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
(    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
)    O
.    O

A    O
,    O
D3    O
,    O
E    O
,    O
B6    O
,    O
B12    O
,    O
folic    O
acid    O
(    O
B9    O
)    O
,    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
(    O
vitamin    O
C    O
)    O
,    O
along    O
with    O
a    O
vitamin    O
K    O
derivative    O
,    O
menadione    O
sodium    O
bisulfite    O
DVL    O
adds    O
these    O
vitamins    O
to    O
an    O
electrolyte    O
premix    O
that    O
has    O
7    O
mineral    O
salts    O
:    O
magnesium    O
acetate    O
,    O
sodium    O
acetate    O
,    O
calcium    O
acetate    O
,    O
potassium    O
chloride    O
,    O
calcium    O
chloride    O
,    O
sodium    O
chloride    O
and    O
sodium    O
diacetate    O
.    O

The    O
fresh    O
shoots    O
of    O
many    O
spruces    O
and    O
pines    O
are    O
a    O
natural    O
source    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
European    O
sailors    O
adopted    O
the    O
practice    O
and    O
spread    O
it    O
across    O
the    O
world    O
.    O

Innis    O
&    O
None    O
-    O
Alcohol    O
free    O
pale    O
ale    O
with    O
added    O
ginseng    O
and    O
vitamin    B-Antidepressant102718811
c    I-Antidepressant102718811

Therapy    O
with    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
and    O
methylene    O
blue    O
are    O
frequently    O
used    O
in    O
the    O
treatment    O
of    O
methemoglobinemia    O
.    O

It    O
also    O
boasts    O
a    O
higher    O
calcium    O
and    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
(    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
)    O
content    O
than    O
lemons    O
.    O

Ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
deficiency    O

It    O
employs    O
one    O
cofactor    O
,    O
ascorbate    B-Antidepressant102718811
.    O

The    O
fruit    O
is    O
an    O
oblong    O
red    O
berry    O
long    O
and    O
broad    O
,    O
ripening    O
in    O
late    O
summer    O
or    O
autumn    O
;    O
they    O
are    O
edible    O
but    O
very    O
sour    O
,    O
and    O
rich    O
in    O
Vitamin    O
C    B-Antidepressant102718811

The    O
berries    O
are    O
edible    O
and    O
rich    O
in    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
though    O
with    O
a    O
very    O
sharp    O
flavor    O
;    O
the    O
thorny    O
shrubs    O
make    O
harvesting    O
them    O
difficult    O
,    O
so    O
in    O
most    O
places    O
,    O
they    O
are    O
not    O
widely    O
consumed    O
.    O

Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
can    O
cause    O
analytical    O
false    O
negatives    O
due    O
to    O
its    O
anti    O
-    O
oxidant    O
properties    O
inhibiting    O
the    O
color    O
reaction    O
.    O

Rohmer    O
was    O
a    O
pioneer    O
in    O
research    O
into    O
prematurity    O
,    O
poliomyelitis    O
,    O
tuberculosis    O
,    O
osteomalacia    O
and    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
He    O
was    O
the    O
director    O
of    O
the    O
pediatric    O
clinic    O
of    O
Strasbourg    O
until    O
his    O
retirement    O
in    O
1947    O
,    O
and    O
made    O
it    O
famous    O
all    O
around    O
Europe    O
.    O

A    O
common    O
pathological    O
disorder    O
concerning    O
the    O
"    O
tunica    O
externa    O
"    O
is    O
scurvy    O
,    O
also    O
known    O
as    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
deficiency    O
.    O

Ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
is    O
an    O
example    O
of    O
this    O
effect    O
.    O

The    O
fruits    O
,    O
sour    O
and    O
rich    O
in    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
can    O
be    O
eaten    O
raw    O
or    O
cooked    O
into    O
a    O
sauce    O
to    O
serve    O
with    O
meat    O
or    O
game    O
.    O

Scurvy    O
(    O
lack    O
of    O
dietary    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
)    O

Maurice    O
Stacey    O
,    O
Professor    O
of    O
Chemistry    O
,    O
worked    O
alongside    O
Sir    O
Norman    O
Haworth    O
to    O
artificially    O
synthesize    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
awarded    O
the    O
1933    O
Meldola    O
Medal    O
of    O
the    O
Royal    O
Society    O
of    O
Chemistry    O
(    O
BSc    O
,    O
PhD    O
,    O
DSc    O
)    O

A    O
typical    O
serving    O
of    O
avocado    O
(    O
100    O
g    O
)    O
is    O
moderate    O
to    O
rich    O
in    O
several    O
B    O
vitamins    O
and    O
vitamin    O
K    O
,    O
with    O
good    O
content    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
vitamin    O
E    O
and    O
potassium    O
(    O
right    O
table    O
,    O
USDA    O
nutrient    O
data    O
)    O
.    O

Scurvy    O
(    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
deficiency    O
)    O
affected    O
the    O
crew    O
.    O

It    O
was    O
burnt    O
due    O
to    O
its    O
inability    O
to    O
maneuver    O
,    O
as    O
a    O
result    O
of    O
the    O
reduced    O
number    O
of    O
the    O
crew    O
as    O
a    O
result    O
of    O
diseases    O
which    O
killed    O
about    O
half    O
the    O
crew    O
,    O
such    O
as    O
scurvy    O
(    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
deficiency    O
)    O
,    O
which    O
was    O
felt    O
acutely    O
while    O
crossing    O
the    O
Indian    O
Ocean    O
.    O

Both    O
lowering    O
the    O
temperature    O
and    O
the    O
addition    O
of    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
seem    O
to    O
prevent    O
oxidation    O
.    O

However    O
,    O
two    O
closely    O
related    O
rat    O
/    O
human    O
members    O
of    O
the    O
family    O
,    O
SVCT1    O
and    O
SVCT2    O
,    O
localized    O
to    O
different    O
tissues    O
of    O
the    O
body    O
,    O
co    O
-    O
transport    O
L    O
-    O
ascorbate    O
(    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
)    O
and    O
Na+    O
with    O
a    O
high    O
degree    O
of    O
specificity    O
and    O
high    O
affinity    O
for    O
the    O
vitamin    O
.    O

Leaves    O
are    O
particularly    O
rich    O
in    O
vitamin    O
A    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
vitamin    O
K    O
,    O
with    O
moderate    O
content    O
of    O
dietary    O
minerals    O
.    O

Also    O
,    O
regucalcin    O
/    O
SMP30-knockout    O
mice    O
are    O
known    O
to    O
induce    O
a    O
suppression    O
in    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
biosynthesis    O
.    O

Vitamin    O
B12    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
thiamin    O

The    O
more    O
knowledgeable    O
also    O
brought    O
dried    O
fruit    O
and    O
vegetables    O
to    O
provide    O
some    O
variety    O
(    O
and    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
)    O
and    O
were    O
a    O
known    O
(    O
to    O
many    O
)    O
scurvy    O
prevention    O
.    O

A    O
known    O
scurvy    O
prevention    O
,    O
as    O
worked    O
out    O
by    O
most    O
navies    O
in    O
the    O
18th    O
century    O
,    O
was    O
found    O
in    O
a    O
diet    O
that    O
contained    O
dried    O
and    O
fresh    O
fruit    O
or    O
vegetables    O
(    O
as    O
finally    O
discovered    O
in    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
rich    O
foods    O
)    O
.    O

Berocca    O
is    O
a    O
brand    O
of    O
effervescent    O
drink    O
and    O
vitamin    O
tablets    O
containing    O
B    O
vitamins    O
and    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
aspartame    O
(    O
phenylalanine    O
)    O
.    O

The    O
leaves    O
contain    O
protein    O
,    O
vitamin    O
A    O
and    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811

Raw    O
yam    O
has    O
only    O
moderate    O
nutrient    O
density    O
,    O
with    O
appreciable    O
content    O
(    O
10%    O
or    O
more    O
of    O
the    O
Daily    O
Value    O
,    O
DV    O
)    O
limited    O
to    O
potassium    O
,    O
vitamin    O
B6    O
,    O
manganese    O
,    O
thiamin    O
,    O
dietary    O
fiber    O
,    O
and    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
(    O
table    O
)    O
.    O

In    O
the    O
past    O
incarnation    O
,    O
the    O
product    O
had    O
only    O
5    O
calories    O
,    O
was    O
sweetened    O
with    O
sucralose    O
,    O
and    O
contained    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
in    O
the    O
form    O
of    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
.    O
in    O
February    O
or    O
March    O
of    O
2016    O
,    O
Fizzies    O
was    O
again    O
discontinued    O
.    O

Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
was    O
isolated    O
by    O
C.C.    O
King    O
at    O
the    O
University    O
of    O
Pittsburgh    O
.    O

Alaska    O
Natives    O
consumed    O
it    O
in    O
bread    O
and    O
pies    O
as    O
a    O
source    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
the    O
Coeur    O
d'Alene    O
people    O
ate    O
the    O
fruit    O
fresh    O
,    O
dried    O
,    O
mashed    O
,    O
cooked    O
,    O
and    O
added    O
it    O
to    O
soup    O
or    O
froze    O
it    O
for    O
later    O
use    O
,    O
and    O
many    O
other    O
groups    O
relished    O
it    O
and    O
stored    O
it    O
frozen    O
,    O
dried    O
,    O
pressed    O
into    O
cakes    O
,    O
or    O
canned    O
for    O
winter    O
use    O
.    O

It    O
was    O
long    O
believed    O
that    O
the    O
men    O
had    O
died    O
from    O
scurvy    O
;    O
an    O
ailment    O
caused    O
by    O
lack    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
and    O
common    O
in    O
polar    O
regions    O
.    O

For    O
example    O
,    O
Jerry    O
Coyne    O
asks    O
why    O
a    O
designer    O
would    O
"    O
give    O
us    O
a    O
pathway    O
for    O
making    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
but    O
then    O
destroy    O
it    O
by    O
disabling    O
one    O
of    O
its    O
enzymes    O
"    O
(    O
see    O
pseudogene    O
)    O
and    O
why    O
a    O
designer    O
would    O
not    O
"    O
stock    O
oceanic    O
islands    O
with    O
reptiles    O
,    O
mammals    O
,    O
amphibians    O
,    O
and    O
freshwater    O
fish    O
,    O
despite    O
the    O
suitability    O
of    O
such    O
islands    O
for    O
these    O
species    O
"    O
.    O

Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
is    O
sometimes    O
added    O
by    O
fortification    O
,    O
because    O
content    O
is    O
variable    O
,    O
and    O
much    O
of    O
that    O
is    O
lost    O
in    O
processing    O
.    O

According    O
to    O
Canadian    O
Food    O
and    O
Drug    O
Regulation    O
,    O
apple    O
juice    O
may    O
contain    O
a    O
Class    O
II    O
preservative    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
amylase    O
,    O
cellulase    O
and    O
pectinase    O
.    O

The    O
onion    O
is    O
rich    O
in    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
was    O
important    O
because    O
of    O
this    O
,    O
and    O
it    O
was    O
widely    O
used    O
as    O
medicinal    O
herb    O
against    O
colds    O
and    O
other    O
infections    O
.    O

Albert    O
Szent    O
-    O
Györgyi    O
,    O
discovered    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
(    O
1932    O
)    O

It    O
studies    O
the    O
use    O
of    O
statin    O
(    O
simvastatin    O
40    O
mg    O
)    O
medication    O
and    O
vitamin    O
supplementation    O
(    O
vitamin    O
E    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
beta    O
carotene    O
)    O
in    O
patients    O
that    O
are    O
at    O
risk    O
for    O
cardiovascular    O
disease    O
.    O

In    O
a    O
100    O
gram    O
amount    O
,    O
raw    O
tomatoes    O
supply    O
18    O
calories    O
and    O
are    O
a    O
moderate    O
source    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
(    O
17%    O
of    O
the    O
Daily    O
Value    O
)    O
,    O
but    O
otherwise    O
are    O
absent    O
of    O
significant    O
nutrient    O
content    O
(    O
table    O
)    O
.    O

Additionally    O
,    O
such    O
a    O
value    O
does    O
not    O
highlight    O
prevalence    O
in    O
types    O
of    O
antioxidants    O
compounds    O
over    O
others    O
(    O
like    O
lycopene    O
versus    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
)    O
,    O
meaning    O
that    O
while    O
a    O
resulting    O
content    O
value    O
between    O
two    O
substances    O
may    O
be    O
similar    O
,    O
though    O
the    O
potential    O
overlying    O
resulting    O
effect    O
can    O
differ    O
,    O
making    O
clinical    O
assessments    O
of    O
resulting    O
symptoms    O
highly    O
unreliable    O
as    O
to    O
the    O
underlying    O
condition    O
.    O

Development    O
of    O
technology    O
for    O
the    O
production    O
of    O
vitamins    O
A1    O
,    O
B1    O
,    O
B2    O
,    O
E    O
,    O
C    B-Antidepressant102718811
and    O
K1    O
;    O

Antioxidants    O
,    O
such    O
as    O
vitamins    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
E    O
,    O
have    O
been    O
proposed    O
to    O
protect    O
against    O
the    O
disease    O
,    O
but    O
results    O
of    O
studies    O
have    O
been    O
contradictory    O
and    O
no    O
positive    O
effect    O
has    O
been    O
proven    O
.    O

|rowspan=2|    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
(    O
Ascorbic    O
acid    O
)    O

However    O
none    O
of    O
these    O
herbs    O
are    O
rich    O
in    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
the    O
usual    O
preparation    O
by    O
extracting    O
of    O
juices    O
would    O
have    O
destroyed    O
most    O
of    O
their    O
content    O
,    O
rendering    O
the    O
preparations    O
ineffectual    O
against    O
true    O
scurvy    O
.    O

Vitamins    O
A    O
,    O
C    B-Antidepressant102718811
and    O
E    O
have    O
been    O
shown    O
to    O
be    O
'    O
free    O
radical    O
scavengers    O
'    O
by    O
studies    O
looking    O
for    O
protective    O
tendencies    O
of    O
antioxidants    O
.    O

Other    O
vitamins    O
to    O
be    O
taken    O
by    O
HIV    O
-    O
infected    O
adults    O
are    O
vitamins    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
E.    O

Usually    O
all    O
15    O
nutrients    O
are    O
shown    O
:    O
calories    O
,    O
calories    O
from    O
fat    O
,    O
fat    O
,    O
saturated    O
fat    O
,    O
trans    O
fat    O
,    O
cholesterol    O
,    O
sodium    O
,    O
carbohydrates    O
,    O
dietary    O
fiber    O
,    O
sugars    O
,    O
protein    O
,    O
vitamin    O
A    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
calcium    O
,    O
and    O
iron    O
.    O

Specifically    O
,    O
blueberries    O
,    O
as    O
a    O
popular    O
superfood    O
example    O
,    O
are    O
not    O
especially    O
nutrient    O
-    O
dense    O
(    O
considered    O
to    O
be    O
a    O
superfood    O
characteristic    O
)    O
,    O
having    O
moderate    O
content    O
of    O
only    O
three    O
essential    O
nutrients    O
:    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
(    O
an    O
antioxidant    O
)    O
,    O
vitamin    O
K    O
and    O
manganese    O
.    O

The    O
soldiers    O
suffered    O
widespread    O
scurvy    O
(    O
due    O
to    O
poor    O
nutrition    O
and    O
lack    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
)    O
,    O
which    O
claimed    O
the    O
lives    O
of    O
over    O
200    O
of    O
the    O
1,120    O
men    O
that    O
first    O
winter    O
.    O

an    O
excellent    O
source    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
(    O
50%    O
)    O
or    O
vitamin    O
A    O
(    O
25%    O
)    O
or    O
folate    O
(    O
25%    O
)    O
or    O
source    O
of    O
fibre    O
(    O
2    O
grams    O
)    O

His    O
evidence    O
for    O
this    O
is    O
a    O
chart    O
based    O
on    O
references    O
for    O
1963    O
and    O
2008    O
which    O
shows    O
values    O
of    O
beta    O
-    O
carotene    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
iron    O
found    O
in    O
spinach    O
and    O
carrot    O
,    O
from    O
which    O
he    O
appears    O
to    O
infer    O
a    O
comparable    O
enzyme    O
deficit    O
in    O
all    O
vegetable    O
food    O
sources    O
.    O

In    O
1920    O
she    O
held    O
a    O
temporary    O
post    O
investigating    O
the    O
nutrition    O
,    O
specifically    O
the    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
content    O
,    O
of    O
mine    O
workers    O
'    O
diets    O
in    O
the    O
area    O
of    O
Johannesburg    O
,    O
and    O
as    O
a    O
result    O
"    O
their    O
health    O
was    O
substantially    O
improved    O
"    O
.    O

To    O
avoid    O
this    O
,    O
local    O
spruce    O
beer    O
began    O
to    O
be    O
used    O
to    O
supplement    O
the    O
rations    O
with    O
additional    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
Spruce    O
beer    O
was    O
not    O
consistently    O
used    O
,    O
however    O
,    O
but    O
primarily    O
in    O
reaction    O
to    O
occurrences    O
of    O
scurvy    O
.    O

In    O
the    O
first    O
step    O
of    O
this    O
pathway    O
,    O
H2O2    O
is    O
reduced    O
to    O
water    O
by    O
ascorbate    O
peroxidase    O
(    O
APX    O
)    O
using    O
ascorbate    B-Antidepressant102718811
as    O
the    O
electron    O
donor    O
.    O

Thus    O
ascorbate    B-Antidepressant102718811
and    O
glutathione    O
are    O
not    O
consumed    O
;    O
the    O
net    O
electron    O
flow    O
is    O
from    O
NADPH    O
to    O
H2O2    O
.    O

The    O
tomatoes    O
are    O
high    O
in    O
lycopene    O
,    O
antioxidants    O
,    O
and    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
The    O
final    O
products    O
may    O
contain    O
up    O
to    O
2–6%    O
of    O
salt    O
and    O
could    O
provide    O
a    O
significant    O
contribution    O
to    O
the    O
day    O
's    O
intake    O
.    O

This    O
squash    O
is    O
rich    O
in    O
beta    O
carotene    O
,    O
with    O
iron    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
potassium    O
,    O
and    O
smaller    O
traces    O
of    O
calcium    O
,    O
folic    O
acid    O
,    O
and    O
minute    O
amounts    O
of    O
B    O
vitamins    O
.    O

In    O
a    O
100    O
gram    O
amount    O
,    O
elderberries    O
supply    O
73    O
calories    O
and    O
are    O
a    O
rich    O
source    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
providing    O
43%    O
of    O
the    O
Daily    O
Value    O
(    O
DV    O
)    O
.    O

Individual    O
fruits    O
weigh    O
between    O
270    O
and    O
480    O
mg    O
and    O
contain    O
high    O
amounts    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
vitamin    O
E    O
,    O
carotenoids    O
,    O
flavonoids    O
and    O
health    O
-    O
beneficial    O
fatty    O
acids    O
,    O
as    O
well    O
as    O
higher    O
amounts    O
of    O
vitamin    O
B12    O
than    O
other    O
fruits    O
.    O

The    O
fruit    O
of    O
the    O
plant    O
has    O
a    O
high    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
content    O
–    O
in    O
a    O
range    O
of    O
114    O
to    O
1550    O
mg    O
per    O
100    O
grams    O
with    O
an    O
average    O
content    O
(    O
695    O
mg    O
per    O
100    O
grams    O
)    O
,    O
placing    O
sea    O
buckthorn    O
fruit    O
among    O
the    O
most    O
enriched    O
plant    O
sources    O
of    O
vitamin    O
C.    O

It    O
was    O
found    O
that    O
when    O
chromium    O
(    O
VI    O
)    O
species    O
formed    O
under    O
physiological    O
conditions    O
,    O
they    O
were    O
reduced    O
by    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
glutathione    O
to    O
form    O
reactive    O
intermediate    O
complexes    O
.    O

Rice    O
water    O
has    O
vitamin    O
B    O
,    O
C    B-Antidepressant102718811
,    O
E    O
,    O
and    O
minerals    O
,    O
which    O
help    O
in    O
tightening    O
skin    O
and    O
shrinkage    O
of    O
open    O
pores    O
on    O
face    O
.    O

Albert    O
Szent    O
-    O
Györgyi    O
isolated    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
around    O
1930    O

Albert    O
Szent    O
-    O
Györgyi    O
discovered    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
created    O
the    O
first    O
artificial    O
vitamin    O
.    O

Albert    O
Szent    O
-    O
Györgyi    O
a    O
Nobel    O
Laureate    O
in    O
Medicine    O
for    O
discover    O
of    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811

When    O
cultured    O
in    O
a    O
“    O
promineralization    O
medium    O
”    O
that    O
contains    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
(    O
known    O
to    O
promote    O
skeletal    O
-    O
like    O
ECM    O
formation    O
in    O
osteoblasts    O
)    O
and    O
a    O
source    O
of    O
phosphate    O
(    O
for    O
hydroxyapatite    O
formation    O
)    O
,    O
C4    O
-    O
2B    O
cells    O
produce    O
and    O
retain    O
approximately    O
8x    O
more    O
mineralized    O
calcium    O
than    O
parental    O
LNCaP    O
cells    O
.    O

Among    O
these    O
materials    O
were    O
sugar    O
and    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
The    O
loss    O
to    O
consumers    O
in    O
watering    O
down    O
procedures    O
has    O
been    O
estimated    O
at    O
$    O
1    O
million    O
in    O
lost    O
value    O
.    O

Valoneic    O
acid    O
dilactone    O
,    O
flavogallonic    O
acid    O
dilactone    O
,    O
gallagyldilactone    O
,    O
ellagic    O
acid    O
and    O
gallic    O
acid    O
are    O
hydrolysable    O
tannins    O
that    O
can    O
be    O
isolated    O
from    O
the    O
heartwood    O
of    O
"    O
S.    O
laeviforia    O
"    O
as    O
well    O
as    O
two    O
stilbenoids    O
,    O
laevifonol    O
(    O
an    O
ε-viniferin    O
-    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
hybrid    O
compound    O
)    O
and    O
laevifoside    O
(    O
an    O
O    O
-    O
glucoside    O
of    O
ampelopsin    O
A    O
)    O
.    O

The    O
predominant    O
type    O
of    O
acerola    O
produced    O
here    O
is    O
the    O
"    O
Olivier    O
"    O
,    O
a    O
variety    O
that    O
is    O
packed    O
with    O
the    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
(    O
1.200    O
mg/100ml    O
of    O
juice    O
and    O
1.400    O
mg/100    O
g    O
of    O
pulp    O
)    O
for    O
which    O
this    O
plant    O
is    O
primarily    O
cultivated    O
and    O
can    O
be    O
cultivated    O
with    O
little    O
pesticide    O
.    O

This    O
is    O
the    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
rich    O
fruit    O
for    O
which    O
Junqueirópolis    O
has    O
been    O
nicknamed    O
"    O
Capital    O
da    O
Acerola    O
"    O
,    O
the    O
"    O
Acerola    O
Capital    O
"    O
.    O

Juice    O
from    O
the    O
ripe    O
berries    O
is    O
astringent    O
,    O
sweet    O
(    O
with    O
high    O
sugar    O
content    O
)    O
,    O
sour    O
(    O
low    O
pH    O
)    O
,    O
and    O
contains    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811

Cooked    O
amaranth    O
leaves    O
are    O
an    O
excellent    O
source    O
of    O
vitamin    O
A    O
,    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
calcium    O
,    O
manganese    O
,    O
and    O
folate    O
.    O

Ascorbic    O
acid    O
is    O
one    O
form    O
(    O
"    O
vitamer    O
"    O
)    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
It    O
was    O
originally    O
called    O
L    O
-    O
hexuronic    O
acid    O
,    O
but    O
,    O
when    O
it    O
was    O
found    O
to    O
have    O
vitamin    O
C    O
activity    O
in    O
animals    O
(    O
"    O
vitamin    O
C    O
"    O
being    O
defined    O
as    O
a    O
vitamin    O
activity    O
,    O
not    O
then    O
a    O
specific    O
substance    O
)    O
,    O
the    O
suggestion    O
was    O
made    O
to    O
rename    O
it    O
.    O

The    O
newly    O
discovered    O
food    O
-    O
factor    O
was    O
eventually    O
called    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811

Eccrine    O
sweat    O
is    O
clear    O
,    O
odorless    O
,    O
and    O
is    O
composed    O
of    O
98–99%    O
water    O
;    O
it    O
also    O
contains    O
NaCl    O
,    O
fatty    O
acids    O
,    O
lactic    O
acid    O
,    O
citric    O
acid    O
,    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
,    O
urea    O
,    O
and    O
uric    O
acid    O
.    O

From    O
about    O
500    O
million    O
years    O
ago    O
,    O
freshwater    O
and    O
terrestrial    O
plants    O
slowly    O
optimized    O
the    O
production    O
of    O
“    O
new    O
”    O
endogenous    O
antioxidants    O
,    O
such    O
as    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
(    O
vitamin    O
C    O
)    O
,    O
natural    O
phenols    O
(    O
including    O
flavonoids    O
)    O
and    O
polyphenols    O
,    O
tocopherols    O
,    O
etc    O
.    O

It    O
has    O
been    O
shown    O
not    O
only    O
that    O
increased    O
levels    O
of    O
protective    O
low    O
molecular    O
weight    O
antioxidants    O
through    O
a    O
diet    O
rich    O
in    O
phytochemicals    O
,    O
but    O
also    O
by    O
direct    O
topical    O
dermal    O
application    O
of    O
low    O
molecular    O
weight    O
antioxidants    O
,    O
notably    O
vitamins    B-Antidepressant102718811
C    I-Antidepressant102718811
and    O
E    O
,    O
as    O
well    O
as    O
lipoic    O
acid    O
,    O
may    O
confer    O
protective    O
effects    O
against    O
oxidative    O
stress    O
.    O

Experiments    O
with    O
binary    O
mixtures    O
of    O
natural    O
phenolic    O
antioxidants    O
with    O
a    O
non    O
-    O
phenolic    O
antioxidant    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
show    O
that    O
phenolics    O
exhibit    O
antagonism    O
when    O
combined    O
with    O
this    O
latter    O
compound    O
.    O

He    O
was    O
also    O
an    O
early    O
proponent    O
of    O
low    O
carb    O
dieting    O
,    O
and    O
recommended    O
the    O
use    O
of    O
numerous    O
supplements    O
,    O
including    O
desiccated    O
liver    O
tablets    O
,    O
225mcg    O
kelp    O
tablets    O
,    O
vitamin    B-Antidepressant102718811
c    I-Antidepressant102718811
tablets    O
,    O
digestive    O
enzymes    O
and    O
raw    O
glandulars    O
such    O
as    O
adrenal    O
and    O
orchic    O
.    O

Originally    O
it    O
was    O
reported    O
that    O
early    O
settlers    O
got    O
their    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
intake    O
,    O
and    O
thus    O
avoided    O
scurvy    O
,    O
by    O
eating    O
hawberries    O
.    O

The    O
potato    O
is    O
also    O
a    O
good    O
source    O
of    O
many    O
vitamins    O
and    O
minerals    O
,    O
particularly    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
(    O
especially    O
when    O
fresh    O
)    O
.    O

However    O
,    O
other    O
research    O
suggests    O
that    O
scurvy    O
(    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
deficiency    O
)    O
and    O
environmental    O
factors    O
also    O
contributed    O
to    O
their    O
deaths    O
.    O

20%    O
of    O
the    O
RDI    O
of    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811

a    O
"    O
good    O
source    O
"    O
(    O
10%    O
of    O
the    O
RDI    O
)    O
of    O
vitamins    O
C    B-Antidepressant102718811
and    O
E.    O

The    O
tea    O
is    O
deep    O
ruby    O
-    O
brown    O
to    O
rich    O
dark    O
maroon    O
in    O
color    O
and    O
is    O
abundant    O
in    O
iron    O
,    O
potassium    O
,    O
and    O
vitamins    O
B    O
and    O
C    B-Antidepressant102718811
It    O
is    O
often    O
garnished    O
with    O
pine    O
nuts    O
.    O

The    O
potato    O
is    O
also    O
a    O
good    O
source    O
of    O
many    O
vitamins    O
and    O
minerals    O
,    O
particularly    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
when    O
fresh    O
.    O

Acetaldehyde    O
is    O
a    O
highly    O
unstable    O
compound    O
and    O
quickly    O
forms    O
free    O
radical    O
structures    O
which    O
are    O
highly    O
toxic    O
if    O
not    O
quenched    O
by    O
antioxidants    O
such    O
as    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
(    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
)    O
and    O
Vitamin    O
B1    O
(    O
thiamine    O
)    O
.    O

During    O
the    O
summer    O
months    O
the    O
trees    O
exhibit    O
round    O
to    O
oval    O
fruit    O
,    O
rich    O
in    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
,    O
with    O
a    O
thick    O
peel    O
covering    O
white    O
slippery    O
pulp    O
,    O
which    O
like    O
the    O
leaves    O
turns    O
increasingly    O
yellow    O
at    O
the    O
end    O
of    O
the    O
blooming    O
season    O
.    O

Every    O
part    O
of    O
the    O
tree    O
is    O
useful    O
and    O
the    O
fruit    O
in    O
particular    O
is    O
used    O
in    O
Ayurvedic    O
medicinal    O
preparations    O
and    O
is    O
rich    O
in    O
Vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811

Many    O
claims    O
have    O
been    O
made    O
about    O
the    O
beneficial    O
effects    O
of    O
aguapanela    O
,    O
based    O
on    O
beliefs    O
such    O
as    O
having    O
more    O
vitamin    B-Antidepressant102718811
C    I-Antidepressant102718811
than    O
orange    O
juice    O
or    O
as    O
many    O
rehydrating    O
minerals    O
as    O
Gatorade    O
.    O

Myrosinase    O
is    O
activated    O
by    O
l-ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
(    O
vitamin    O
C    O
)    O
under    O
the    O
influence    O
of    O
the    O
pH    O
,    O
and    O
higher    O
myrosinase    O
activity    O
has    O
been    O
shown    O
in    O
damaged    O
cabbage    O
leaves    O
,    O
while    O
its    O
activity    O
is    O
reduced    O
by    O
cooking    O
the    O
leaves    O
,    O
although    O
the    O
glucosinolates    O
can    O
then    O
be    O
transformed    O
to    O
allyl    O
cyanide    O
by    O
microflora    O
in    O
the    O
intestines    O
.    O

Malic    O
acid    O
,    O
ascorbic    B-Antidepressant102718811
acid    I-Antidepressant102718811
,    O
citric    O
acid    O
,    O
ketoglutaric    O
acid    O
,    O
fumaric    O
acid    O
,    O
shikimic    O
acid    O
and    O
traces    O
of    O
succinic    O
acid    O
were    O
detected    O
.    O

eprobemide    B-Antidepressant102718811
(    O
INN    O
)    O

25E    O
-    O
NBOMe    O
(    O
2C    O
-    O
E    O
-    O
NBOMe    O
,    O
NBOMe-2C    O
-    O
E    O
)    O
is    O
a    O
derivative    O
of    O
the    O
phenethylamine    O
2C-E    B-Antidepressant102718811
It    O
acts    O
in    O
a    O
similar    O
manner    O
to    O
related    O
compounds    O
such    O
as    O
25I    O
-    O
NBOMe    O
,    O
which    O
are    O
potent    O
agonists    O
at    O
the    O
5HT2A    O
receptor    O
.    O

On    O
May    O
7    O
,    O
2011    O
,    O
in    O
the    O
United    O
States    O
,    O
two    O
young    O
adults    O
died    O
after    O
overdosing    O
on    O
Bromo    O
-    O
DragonFLY    O
,    O
which    O
they    O
thought    O
was    O
2C-E    B-Antidepressant102718811
,    O
and    O
several    O
others    O
were    O
hospitalized    O
during    O
the    O
same    O
incident    O
.    O

Escitalopram    B-Antidepressant102718811
(    O
Lexapro    O
)    O
,    O
SSRI    O

Selective    O
serotonin    O
reuptake    O
inhibitors    O
(    O
SSRIs    O
)    O
,    O
such    O
as    O
sertraline    O
(    O
Zoloft    O
,    O
Lustral    O
)    O
,    O
escitalopram    B-Antidepressant102718811
(    O
Lexapro    O
,    O
Cipralex    O
)    O
,    O
fluoxetine    O
(    O
Prozac    O
)    O
,    O
paroxetine    O
(    O
Seroxat    O
)    O
,    O
and    O
citalopram    B-Antidepressant102718811
,    O
are    O
the    O
primary    O
medications    O
considered    O
,    O
due    O
to    O
their    O
relatively    O
mild    O
side    O
effects    O
and    O
broad    O
effect    O
on    O
the    O
symptoms    O
of    O
depression    O
and    O
anxiety    O
,    O
as    O
well    O
as    O
reduced    O
risk    O
in    O
overdose    O
,    O
compared    O
to    O
their    O
older    O
tricyclic    O
alternatives    O
.    O

A    O
double    O
-    O
blinded    O
,    O
placebo    O
-    O
controlled    O
trial    O
focusing    O
on    O
women    O
with    O
major    O
depressive    O
disorder    O
found    O
that    O
daily    O
creatine    O
supplementation    O
adjunctive    O
to    O
escitalopram    B-Antidepressant102718811
was    O
more    O
effective    O
than    O
escitalopram    O
alone    O
.    O

Escitalopram    B-Antidepressant102718811

Pharmacological    O
interventions    O
include    O
the    O
use    O
of    O
SSRIs    O
,    O
such    O
as    O
fluvoxamine    O
,    O
citalopram    B-Antidepressant102718811
,    O
escitalopram    B-Antidepressant102718811
,    O
and    O
naltrexone    O

Many    O
other    O
SSRI    O
antidepressants    O
are    O
fluorinated    O
organics    O
,    O
including    O
Celexa    B-Antidepressant102718811
,    O
Luvox    O
,    O
and    O
Lexapro    B-Antidepressant102718811
.    O

It    O
also    O
binds    O
to    O
the    O
allosteric    O
site    O
of    O
the    O
serotonin    O
transporter    O
,    O
similarly    O
,    O
but    O
less    O
potently    O
,    O
than    O
escitalopram    B-Antidepressant102718811
.    O

Escitalopram    B-Antidepressant102718811

A    O
brand    O
name    O
for    O
Escitalopram    B-Antidepressant102718811

D-Deprenyl    B-Antidepressant102718811
,    O
MAO    O
-    O
B    O
inhibitor    O
prodrug    O
that    O
metabolizes    O
into    O
both    O
D    O
-    O
amphetamine    O
and    O
D    O
-    O
methamphetamine    O

Hosanna    O
KABAKORO    O
-    O
Kabara    O
-    O
Glenn    O
KABLE    O
-    O
Kadavu    O
fantail    O
-    O
Kadavu    O
Group    O
-    O
Kadavu    O
honeyeater    O
-    O
Kadavu    O
Island    O
-    O
Penaia    O
KADAVULEVU    O
-    O
Kaibu    O
-    O
Simione    O
KAITANI    O
-    O
Kaivalagi    O
-    O
Kaiviti    O
-    O
Sekonaia    O
KALOU    O
-    O
Atunaisa    O
KALOUMAIRAI    O
-    O
KALOUYALEWA    O
-    O
Daren    O
KAMALI    O
-    O
Tomasi    O
KANAILAGI    O
-    O
Kanacea    O
-    O
Kanaka    O
-    O
Ratu    O
Epeli    O
KANAKANA    O
-    O
Kanakas    O
-    O
Malakai    O
KAINIHEWE    O
-    O
Mari    O
KAPI    O
-    O
Kasavu    O
River    O
-    O
Wise    O
KATIVERATA    O
-    O
Kato'aga    O
-    O
Ratu    O
Aisea    O
KATONIVERE    O
-    O
Jonetani    O
KAUKIMOCE    O
-    O
Kaunitoni    O
-    O
Malakai    O
KAUNIVALU    O
-    O
Samuela    O
KAUTOGA    O
-    O
Kava    O
-    O
Kava    O
culture    O
-    O
Kavain    O
-    O
Kavalactone    B-Antidepressant102718811
-    O
Kavula    O
River    O
-    O
"    O
Adi    O
"    O
Salaseini    O
KAVUNONO    O
-    O
Nemani    O
KAVURU    O
-    O
Francis    O
KEAN    O
-    O
Freddy    O
KEIAHO    O
-    O
Kenneth    O
KEITH    O
-    O
Declan    O
KELLY    O
-    O
Nemia    O
KENATALE    O
-    O
Kendrit    O
Shiri    O
Sanatan    O
Dharam    O
Shiv    O
Temple    O
-    O
Ro    O
Teimumu    O
KEPA    O
-    O
Sailosi    O
KEPA    O
-    O
Iliesa    O
KERESONI    O
-    O
Samu    O
KEREVI    O
-    O
Rashit    O
KHAMIDULIN    O
-    O
Tulsi    O
Ram    O
KHELWAN    O
-    O
Shah    O
KIBRIA    O
-    O
Lyons    O
KIERAN    O
-    O
Viliame    O
KIKAU    O
-    O
Kingiodendron    O
platycarpum    O
-    O
Kioa    O
-    O
Kisan    O
Sangh    O
-    O
Arthur    O
KITINAS    O
-    O
Kleinhovia    O
-    O
Meli    O
KOLIAVU    O
-    O
Osea    O
KOLINISAU    O
-    O
George    O
KONROTE    O
-    O
Sevanaia    O
KORO    O
-    O
Koro    O
Airport    O
-    O
Koro    O
Island    O
-    O
Koro    O
-    O
ni    O
-    O
O    O
-    O
Koro    O
Sea    O
-    O
Jimi    O
KOROI    O
-    O
Jokapeci    O
KOROI    O
-    O
Marika    O
KOROIBETE    O
-    O
Kiniviliame    O
KOROIBULEKA    O
-    O
Josua    O
KOROIBULU    O
-    O
Semi    O
KOROILAVESAU    O
-    O
Apisai    O
KOROISAU    O
-    O
Koroivonu    O
River    O
-    O
Korolevu    O
River    O
-    O
Koro    O
-    O
ni    O
-    O
O    O
-    O
Korotasere    O
River    O
-    O
Niumaia    O
KOROVATA    O
-    O
Lesi    O
KOROVAVALA    O
-    O
Korovou    O
-    O
Al    O
KOROVOU    O
-    O
Manu    O
KOROVULAVULA    O
-    O
Korovuli    O
River    O
-    O
Koroyanitu    O
,    O
Mount    O
-    O
Sunia    O
KOTO    O
-    O
Joji    O
KOTOBALAVU    O
-    O
Faiyaz    O
KOYA    O
-    O
Sidiq    O
KOYA    O
-    O
Nailani    O
KRISHAN    O
-    O
James    O
Shri    O
KRISHNA    O
-    O
Roy    O
KRISHNA    O
-    O
Ratu    O
Inoke    O
KUBUABOLA    O
-    O
Ratu    O
Jone    O
KUBUABOLA    O
-    O
Sisa    O
KOYAMAIBOLE    O
-    O
Kubuna    O
Confederacy    O
-    O
Kubuna    O
River    O
-    O
Kula    O
Eco    O
Park    O
-    O
Kulu    O
Bay    O
Resort    O
-    O
Semi    O
KUNATANI    O
-    O
Maleli    O
KUNAVORE    O
-    O
Sadhu    O
KUPPUSWAMI    O
-    O
Jone    O
KURADUADUA    O
-    O
Chris    O
KURIDRANI    O
-    O
Tevita    O
KURIDRANI    O
-    O
Selina    O
KURULECA    O
-    O
Suliasi    O
KURULO    O
-    O
Kundan    O
Singh    O
KUSH    O
-    O
Kya    O
Dilli    O
Kya    O
Lahore    O

Desmethoxyyangonin    O
or    O
5,6-dehydrokawain    O
is    O
one    O
of    O
the    O
six    O
major    O
kavalactone    B-Antidepressant102718811
found    O
in    O
the    O
"    O
Piper    O
methysticum    O
"    O
(    O
kava    O
)    O
plant    O
.    O

Kavain    O
is    O
the    O
main    O
kavalactone    B-Antidepressant102718811
found    O
mostly    O
in    O
the    O
roots    O
of    O
the    O
kava    O
plant    O
.    O

dimetacrine    B-Antidepressant102718811
(    O
INN    O
)    O

Mycobacterium    B-Antidepressant102718811
vaccae    I-Antidepressant102718811
is    O
a    O
nonpathogenic    O
species    O
of    O
the    O
Mycobacteriaceae    O
family    O
of    O
bacteria    O
that    O
lives    O
naturally    O
in    O
soil    O
.    O

Protriptyline    O
is    O
a    O
tricyclic    O
compound    O
,    O
specifically    O
a    O
dibenzocycloheptadiene    B-Antidepressant102718811
,    O
and    O
possesses    O
three    O
rings    O
fused    O
together    O
with    O
a    O
side    O
chain    O
attached    O
in    O
its    O
chemical    O
structure    O
.    O

Metralindole    B-Antidepressant102718811
(    O
INN    O
)    O

Amoxapine    B-Antidepressant102718811

Along    O
with    O
trimipramine    O
,    O
iprindole    B-Antidepressant102718811
,    O
and    O
amoxapine    B-Antidepressant102718811
,    O
it    O
has    O
been    O
described    O
as    O
an    O
"    O
atypical    O
"    O
or    O
"second-generation"    B-Antidepressant102718811
TCA    O
due    O
to    O
its    O
relatively    O
late    O
introduction    O
and    O
atypical    O
pharmacology    O
.    O

Nortriptyline    O
,    O
desipramine    O
,    O
and    O
amoxapine    B-Antidepressant102718811
are    O
tricyclic    O
antidepressants    O
and    O
secondary    O
amines    O
.    O

Amoxapine    B-Antidepressant102718811

Tiazesim    O
(    O
Altinil    O
)    O
and    O
tofenacin    O
(    O
Elamol    O
,    O
Tofacine    O
)    O
are    O
technically    O
not    O
TCAs    O
,    O
but    O
are    O
heterocyclic    B-Antidepressant102718811
antidepressant    I-Antidepressant102718811
that    O
are    O
very    O
closely    O
related    O
,    O
and    O
similarly    O
to    O
various    O
TCAs    O
,    O
are    O
no    O
longer    O
marketed    O
.    O

Certain    O
antidepressants    O
e.g.    O
Azaloxan    B-Antidepressant102718811
&    O
Idazoxan    O
.    O

CX157    B-Antidepressant102718811
(    O
proposed    O
trade    O
name    O
TriRima    B-Antidepressant102718811
,    O
formerly    O
Tyrima    B-Antidepressant102718811
)    O
is    O
a    O
selective    O
and    O
reversible    O
inhibitor    O
of    O
MAO    O
-    O
A    O
(    O
RIMA    O
)    O
.    O

Butriptyline    O
(    O
Evadyne    O
)    O
,    O
demexiptiline    O
(    O
Deparon    O
,    O
Tinoran    O
)    O
,    O
fluacizine    O
(    O
Phtorazisin    O
)    O
,    O
imipraminoxide    B-Antidepressant102718811
(    O
Imiprex    O
,    O
Elepsin    O
)    O
,    O
iprindole    B-Antidepressant102718811
(    O
Prondol    O
,    O
Galatur    O
,    O
Tetran    O
)    O
,    O
metapramine    B-Antidepressant102718811
(    O
Timaxel    O
)    O
,    O
propizepine    B-Antidepressant102718811
(    O
Depressin    O
,    O
Vagran    O
)    O
,    O
and    O
quinupramine    B-Antidepressant102718811
(    O
Kinupril    O
,    O
Kevopril    O
)    O
were    O
also    O
formerly    O
marketed    O
,    O
but    O
have    O
since    O
been    O
discontinued    O
.    O

While    O
most    O
clinically    O
useful    O
TNF    O
inhibitors    O
are    O
monoclonal    O
antibodies    O
,    O
some    O
are    O
simple    O
molecules    O
such    O
as    O
xanthine    O
derivatives    O
(    O
e.g.    O
pentoxifylline    O
)    O
and    O
bupropion    B-Antidepressant102718811
.    O
Bupropion    O
is    O
the    O
active    O
ingredient    O
in    O
the    O
smoking    O
cessation    O
aid    O
Zyban    O
and    O
the    O
antidepressants    O
Wellbutrin    O
and    O
Aplenzin    O
.    O

Some    O
of    O
those    O
medicines    O
include    O
:    O
zidovudine    O
(    O
AZT    O
,    O
AIDS    O
)    O
,    O
acyclovir    O
(    O
Zovirax    O
,    O
anti    O
-    O
herpes    O
)    O
,    O
permethrin    O
(    O
Rid    O
,    O
head    O
and    O
body    O
lice    O
)    O
,    O
bupropion    B-Antidepressant102718811
(    O
Wellbutrin    O
,    O
antidepressant    O
)    O
,    O
colfosceril    O
palmitate    O
(    O
Exosurf    O
,    O
infant    O
acute    O
respiratory    O
distress    O
)    O
,    O
remifentanil    O
(    O
Ultiva    O
,    O
analgesic    O
/    O
anesthetic    O
)    O
,    O
sumatriptan    O
(    O
Imigran    O
,    O
migraine    O
)    O
,    O
salmeterol    O
(    O
Serement    O
,    O
asthma    O
)    O
,    O
tacrine    O
(    O
Cognex    O
,    O
Alzheimers    O
)    O
,    O
gabapentin    O
(    O
Neurontin    O
,    O
epilepsy    O
and    O
neuropathic    O
pain    O
)    O
,    O
troglitazone    O
(    O
Rezulin    O
,    O
diabetes    O
)    O
,    O
and    O
atorvastatin    O
(    O
Lipitor    O
,    O
cholesterol    O
lowering    O
)    O
.    O

Of    O
medicines    O
,    O
bupropion    B-Antidepressant102718811
and    O
varenicline    O
are    O
not    O
legally    O
available    O
in    O
North    O
Korea    O
,    O
but    O
herbal    O
medicines    O
are    O
used    O
as    O
smoking    O
cessation    O
aids    O
.    O

bupropion    B-Antidepressant102718811

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
2,5-dimethoxy-4-methylamphetamine    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    O
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    B-Antidepressant102718811
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    B-Antidepressant102718811
)    O
,    O
and    O
vasopressors    O
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

A    O
class    O
action    O
suit    O
has    O
been    O
filed    O
against    O
Biovail    O
by    O
investors    O
who    O
between    O
December    O
14    O
,    O
2006    O
,    O
and    O
July    O
19    O
,    O
2007    O
,    O
bought    O
Biovail    O
stock    O
,    O
alleging    O
that    O
the    O
company    O
had    O
failed    O
to    O
disclose    O
that    O
the    O
multi    O
-    O
dose    O
study    O
on    O
depression    O
drug    O
Aplenzin    B-Antidepressant102718811
would    O
not    O
be    O
sufficient    O
for    O
the    O
FDA    O
to    O
approve    O
it    O
.    O

Bupropion    B-Antidepressant102718811
(    O
Wellbutrin    O
,    O
Zyban    O
)    O

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
dl-2,5-dimethoxy-4-methylamphetamine    O
DOM    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
MDA    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    O
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
levomethamphetamine    O
and    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    B-Antidepressant102718811
and    O
phenelzine    O
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    B-Antidepressant102718811
)    O
,    O
and    O
vasopressors    O
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

As    O
of    O
2013    O
,    O
the    O
10    O
most    O
prescribed    O
psychiatric    O
drugs    O
by    O
number    O
of    O
prescriptions    O
were    O
alprazolam    O
,    O
sertraline    O
,    O
citalopram    B-Antidepressant102718811
,    O
fluoxetine    O
,    O
lorazepam    O
,    O
trazodone    O
,    O
escitalopram    B-Antidepressant102718811
,    O
duloxetine    O
,    O
bupropion    B-Antidepressant102718811
XL    I-Antidepressant102718811
,    O
and    O
venlafaxine    B-Antidepressant102718811
XR    I-Antidepressant102718811
.    O

Bupropion    B-Antidepressant102718811
(    O
Wellbutrin    O
)    O
,    O
NDRI    B-Antidepressant102718811

Another    O
popular    O
option    O
is    O
to    O
switch    O
to    O
the    O
atypical    O
antidepressant    O
bupropion    B-Antidepressant102718811
(    O
Wellbutrin    O
)    O
or    O
to    O
add    O
bupropion    O
to    O
the    O
existing    O
therapy    O
;    O
this    O
strategy    O
is    O
possibly    O
more    O
effective    O
.    O

Bupropion    B-Antidepressant102718811
,    O
which    O
is    O
used    O
primarily    O
as    O
an    O
antidepressant    O
and    O
smoking    O
cessation    O
aid    O
,    O
is    O
contraindicated    O
in    O
persons    O
experiencing    O
abrupt    O
withdrawal    O
from    O
benzodiazepines    O
or    O
other    O
sedative    O
-    O
hypnotics    O
(    O
e.g.    O
alcohol    O
)    O
,    O
due    O
to    O
an    O
increased    O
risk    O
of    O
seizures    O
.    O

A    O
bioequivalency    O
profile    O
comparison    O
of    O
150    O
mg    O
extended    O
-    O
release    O
bupropion    B-Antidepressant102718811
as    O
produced    O
by    O
Impax    O
Laboratories    O
for    O
Teva    O
and    O
Biovail    O
for    O
GlaxoSmithKline    O
.    O

Medications    O
such    O
as    O
bupropion    B-Antidepressant102718811
may    O
also    O
result    O
in    O
tinnitus    O
.    O

Several    O
other    O
medications    O
,    O
often    O
ones    O
originally    O
used    O
in    O
other    O
contexts    O
,    O
have    O
also    O
been    O
shown    O
to    O
be    O
effective    O
including    O
bupropion    B-Antidepressant102718811
and    O
modafinil    O
.    O

It    O
was    O
to    O
be    O
sold    O
,    O
when    O
combined    O
with    O
bupropion    B-Antidepressant102718811
,    O
under    O
the    O
brand    O
name    O
Empatic    O
,    O
until    O
its    O
development    O
was    O
discontinued    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    O
,    O
phentermine    O
,    O
mephentermine    O
,    O
bupropion    B-Antidepressant102718811
,    O
methoxyphenamine    O
,    O
selegiline    B-Antidepressant102718811
,    O
amfepramone    O
,    O
pyrovalerone    O
,    O
MDMA    O
(    O
ecstasy    O
)    O
,    O
and    O
DOM    O
(    O
STP    O
)    O
.    O

Bupropion    B-Antidepressant102718811
(    O
Zyban    O
,    O
Wellbutrin    O
)    O
-    O
Ganglion    O
blocker    O

Naltrexone    O
is    O
also    O
used    O
in    O
formulation    O
with    O
bupropion    B-Antidepressant102718811
(    O
bupropion    O
/    O
naltrexone    O
)    O
to    O
treat    O
obesity    O
in    O
the    O
United    O
States    O
.    O

Commonly    O
used    O
ones    O
are    O
venlafaxine    B-Antidepressant102718811
,    O
nefazadone    O
,    O
bupropion    B-Antidepressant102718811
,    O
mirtazapine    B-Antidepressant102718811
and    O
trazodone    O
.    O

Azepindole    B-Antidepressant102718811

It    O
is    O
a    O
combination    O
of    O
clofexamide    B-Antidepressant102718811
,    O
an    O
antidepressant    O
,    O
and    O
phenylbutazone    O
,    O
a    O
nonsteroidal    O
anti    O
-    O
inflammatory    O
drug    O
(    O
NSAID    O
)    O
.    O

Levorphanol    O
acts    O
predominantly    O
as    O
an    O
agonist    O
of    O
the    O
μ-opioid    O
receptor    O
(    O
MOR    O
)    O
,    O
but    O
is    O
also    O
an    O
agonist    O
of    O
the    O
δ-opioid    O
receptor    O
(    O
DOR    O
)    O
,    O
κ-opioid    O
receptor    O
(    O
KOR    O
)    O
,    O
and    O
the    O
nociceptin    O
receptor    O
(    O
NOP    O
)    O
,    O
as    O
well    O
as    O
an    O
NMDA    O
receptor    O
antagonist    O
and    O
a    O
serotonin-norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
SNRI    O
)    O
.    O

It    O
acts    O
as    O
a    O
serotonin-norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
,    O
and    O
based    O
on    O
its    O
close    O
relation    O
to    O
orphenadrine    O
,    O
may    O
also    O
possess    O
anticholinergic    O
and    O
antihistamine    O
properties    O
.    O

As    O
a    O
MAO    O
inhibitor    O
,    O
safinamide    O
can    O
theoretically    O
cause    O
hypertensive    O
crises    O
,    O
serotonin    O
syndrome    O
and    O
other    O
severe    O
side    O
effects    O
when    O
combined    O
with    O
other    O
MAO    O
inhibitors    O
or    O
with    O
drugs    O
that    O
are    O
known    O
to    O
interact    O
with    O
MAO    O
inhibitors    O
,    O
such    O
as    O
pethidine    O
,    O
dextromethorphan    O
,    O
serotonin–noradrenaline    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
SNRIs    O
)    O
,    O
tricyclic    O
and    O
tetracyclic    B-Antidepressant102718811
antidepressant    I-Antidepressant102718811
.    O

For    O
a    O
list    O
of    O
NRIs    O
that    O
act    O
at    O
multiple    O
MATs    O
,    O
see    O
the    O
other    O
monoamine    O
reuptake    O
inhibitor    O
pages    O
such    O
as    O
NDRI    B-Antidepressant102718811
,    O
SNRI    B-Antidepressant102718811
,    O
and    O
SNDRI    O
.    O

Medications    O
include    O
SSRIs    O
or    O
SNRIs    B-Antidepressant102718811
are    O
first    O
line    O
choices    O
for    O
generalized    O
anxiety    O
disorder    O
.    O

Duloxetine    O
(    O
Cymbalta    O
)    O
,    O
SNRI    B-Antidepressant102718811

As    O
a    O
prodrug    O
of    O
levorphanol    O
,    O
levomethorphan    O
functions    O
as    O
a    O
potent    O
agonist    O
of    O
all    O
three    O
of    O
the    O
opioid    O
receptors    O
,    O
μ    O
,    O
κ    O
(    O
κ1    O
and    O
κ3    O
but    O
notably    O
not    O
κ2    O
)    O
,    O
and    O
δ    O
,    O
as    O
an    O
NMDA    O
receptor    O
antagonist    O
,    O
and    O
as    O
a    O
serotonin-norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
.    O

Pharmaceutical    O
treatments    O
can    O
include    O
tricyclic    O
antidepressants    O
,    O
atypical    O
antipsychotics    O
,    O
or    O
a    O
combination    O
of    O
an    O
antidepressant    O
from    O
the    O
newer    O
,    O
more    O
well    O
tolerated    O
SSRI    O
or    O
SNRI    B-Antidepressant102718811
categories    O
and    O
an    O
atypical    O
antipsychotic    O
.    O

However    O
,    O
in    O
small    O
clinical    O
trials    O
,    O
using    O
similar    O
doses    O
,    O
butriptyline    O
was    O
found    O
to    O
be    O
similarly    O
effective    O
to    O
amitriptyline    O
and    O
imipramine    O
as    O
an    O
antidepressant    O
,    O
despite    O
the    O
fact    O
that    O
both    O
of    O
these    O
TCAs    O
are    O
far    O
stronger    O
as    O
both    O
5-HT2    O
antagonists    O
and    O
serotonin–norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
.    O

The    O
majority    O
of    O
currently    O
approved    O
antidepressants    O
act    O
predominantly    O
or    O
exclusively    O
as    O
MRIs    O
,    O
including    O
the    O
selective    O
serotonin    O
reuptake    O
inhibitors    O
(    O
SSRIs    O
)    O
,    O
serotonin–norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
SNRIs    O
)    O
,    O
and    O
almost    O
all    O
of    O
the    O
tricyclic    O
antidepressants    O
(    O
TCAs    O
)    O
.    O

Serotonin–norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
SNRI    O
)    O

For    O
example    O
,    O
SSRIs    O
,    O
SNRI    B-Antidepressant102718811
and    O
tricyclic    O
antidepressants    O
acting    O
on    O
serotonin    O
,    O
norepinephrine    O
,    O
dopamine    O
and    O
cannabinoid    O
receptors    O
have    O
been    O
shown    O
to    O
be    O
immunomodulatory    O
and    O
anti    O
-    O
inflammatory    O
against    O
pro    O
-    O
inflammatory    O
cytokine    O
processes    O
,    O
specifically    O
on    O
the    O
regulation    O
of    O
IFN    O
-    O
gamma    O
and    O
IL-10    O
,    O
as    O
well    O
as    O
TNF    O
-    O
alpha    O
and    O
IL-6    O
through    O
a    O
psychoneuroimmunological    O
process    O
.    O

SSRIs    O
,    O
SNRIs    B-Antidepressant102718811
and    O
tricyclic    O
antidepressants    O
acting    O
on    O
serotonin    O
,    O
norepinephrine    O
and    O
dopamine    O
receptors    O
have    O
been    O
shown    O
to    O
be    O
immunomodulatory    O
and    O
anti    O
-    O
inflammatory    O
against    O
pro    O
-    O
inflammatory    O
cytokine    O
processes    O
,    O
specifically    O
on    O
the    O
regulation    O
of    O
Interferon    O
-    O
gamma    O
(    O
IFN    O
-    O
gamma    O
)    O
and    O
Interleukin-10    O
(    O
IL-10    O
)    O
,    O
as    O
well    O
as    O
TNF    O
-    O
alpha    O
and    O
Interleukin-6    O
(    O
IL-6    O
)    O
.    O

Serotonin–norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
SNRI    O
)    O
–    O

Teniloxazine    B-Antidepressant102718811
(    O
Lucelan    O
,    O
Metatone    O
)    O

Pirlindole    B-Antidepressant102718811
(    O
Pirazidol    O
)    O

Pirlindole    B-Antidepressant102718811
(    O
Pirazidol    O
)    O

Minitran    B-Antidepressant102718811

Pridefine    B-Antidepressant102718811
(    O
AHR-1,118    B-Antidepressant102718811
)    O
is    O
a    O
drug    O
which    O
was    O
investigated    O
as    O
an    O
antidepressant    O
in    O
the    O
late    O
1970s    O
and    O
early    O
1980s    O
,    O
but    O
was    O
never    O
marketed    O
.    O

5-MeO-αET    B-Antidepressant102718811

Bazinaprine    B-Antidepressant102718811
(    O
INN    O
)    O

Vortioxetine    B-Antidepressant102718811
(    O
Ki    O
=    O
54    O
nM    O
)    O

Vortioxetine    B-Antidepressant102718811
(    O
Ki    O
=    O
3.7    O
nM    O
)    O

Vortioxetine    B-Antidepressant102718811
(    O
Ki    O
=    O
19    O
nM    O
)    O

Vortioxetine    B-Antidepressant102718811

:    O
N06AA19    O
Amineptine    B-Antidepressant102718811

Amineptine    B-Antidepressant102718811
"    O
(    O
added    O
by    O
2010    O
Regulations    O
)    O
"    O

Amineptine    B-Antidepressant102718811

amineptine    B-Antidepressant102718811

5-MeO-AMT    B-Antidepressant102718811

The    O
"    O
O    O
"-    O
methylated    O
analogue    O
of    O
αMS    O
,    O
5-MeO-αMT    B-Antidepressant102718811
,    O
also    O
readily    O
enters    O
the    O
brain    O
and    O
could    O
be    O
used    O
for    O
this    O
purpose    O
as    O
well    O
.    O

The    O
propyl    O
derivative    O
and    O
bottromycin    O
A2    O
had    O
similar    O
antimicrobial    O
activity    O
to    O
linezolid    B-Antidepressant102718811
,    O
a    O
synthetic    O
antibiotic    O
active    O
against    O
Gram    O
-    O
positive    O
bacteria    O
including    O
MRSA    O
and    O
VRE    O
,    O
across    O
all    O
the    O
bacterial    O
strains    O
studied    O
.    O

Antimicrobials    O
that    O
may    O
lead    O
to    O
sideroblastic    O
anemia    O
include    O
isoniazid    O
,    O
chloramphenicol    O
,    O
cycloserine    O
,    O
and    O
linezolid    B-Antidepressant102718811
.    O

Following    O
a    O
40-year    O
break    O
in    O
discovering    O
new    O
classes    O
of    O
antibacterial    O
compounds    O
,    O
four    O
new    O
classes    O
of    O
antibiotics    O
have    O
been    O
brought    O
into    O
clinical    O
use    O
in    O
the    O
late    O
2000s    O
and    O
early    O
2010s    O
:    O
cyclic    O
lipopeptides    O
(    O
such    O
as    O
daptomycin    O
)    O
,    O
glycylcyclines    O
(    O
such    O
as    O
tigecycline    O
)    O
,    O
oxazolidinones    O
(    O
such    O
as    O
linezolid    B-Antidepressant102718811
)    O
,    O
and    O
lipiarmycins    O
(    O
such    O
as    O
fidaxomicin    O
)    O
.    O

It    O
is    O
sometimes    O
used    O
in    O
combination    O
with    O
other    O
antibiotics    O
that    O
have    O
different    O
mechanisms    O
of    O
action    O
,    O
like    O
vancomycin    O
,    O
linezolid    B-Antidepressant102718811
,    O
daptomycin    O
,    O
and    O
tigecycline    O
.    O

A    O
new    O
class    O
of    O
antibiotics    O
,    O
oxazolidinones    B-Antidepressant102718811
,    O
became    O
available    O
in    O
the    O
1990s    O
,    O
and    O
the    O
first    O
commercially    O
available    O
oxazolidinone    O
,    O
linezolid    B-Antidepressant102718811
,    O
is    O
comparable    O
to    O
vancomycin    O
in    O
effectiveness    O
against    O
MRSA    O
.    O

These    O
strains    O
include    O
:    O
penicillin    O
-    O
resistant    O
"    O
Enterococcus    O
"    O
,    O
vancomycin    O
-    O
resistant    O
"    O
Enterococcus    O
"    O
,    O
and    O
linezolid    B-Antidepressant102718811
-    O
resistant    O
"    O
Enterococcus    O
"    O
.    O

Among    O
these    O
are    O
:    O
ingestion    O
of    O
methanol    O
(    O
wood    O
alcohol    O
)    O
,    O
ethylene    O
glycol    O
(    O
automotive    O
antifreeze    O
)    O
,    O
disulfiram    O
(    O
used    O
to    O
treat    O
chronic    O
alcoholism    O
)    O
,    O
halogenated    O
hydroquinolones    O
(    O
amebicidal    O
medications    O
)    O
,    O
ethambutol    O
and    O
isoniazid    O
(    O
tuberculosis    O
treatment    O
)    O
,    O
and    O
antibiotics    O
such    O
as    O
linezolid    B-Antidepressant102718811
and    O
chloramphenicol    O
.    O

The    O
agents    O
that    O
are    O
used    O
include    O
daptomycin    O
,    O
linezolid    B-Antidepressant102718811
,    O
telavancin    O
,    O
ceftaroline    O
,    O
quinupristin    O
–    O
dalfopristin    O
.    O

This    O
beverage    O
is    O
made    O
by    O
boiling    O
two    O
plants    O
,    O
Mariri    O
(    O
"    O
Banisteriopsis    B-Antidepressant102718811
caapi    I-Antidepressant102718811
"    O
)    O
and    O
Chacrona    O
(    O
"    O
Psychotria    O
viridis    O
"    O
)    O
,    O
both    O
of    O
which    O
are    O
found    O
in    O
the    O
Amazon    O
rainforest    O
.    O

Banisteriopsis    B-Antidepressant102718811
caapi    I-Antidepressant102718811

Ayahuasca    O
,    O
psychoactive    O
concoction    O
prepared    O
from    O
the    O
Amazonian    O
vine    O
"    O
Banisteriopsis    B-Antidepressant102718811
caapi    I-Antidepressant102718811
"    O

Ayahuasca    O
(;    O
)    O
,    O
or    O
iowaska    O
,    O
or    O
yagé    O
(    O
or    O
)    O
,    O
is    O
an    O
entheogenic    O
brew    O
made    O
out    O
of    O
"    O
Banisteriopsis    B-Antidepressant102718811
caapi    I-Antidepressant102718811
"    O
vine    O
and    O
other    O
ingredients    O
.    O

This    O
word    O
refers    O
both    O
to    O
the    O
liana    O
"    O
Banisteriopsis    B-Antidepressant102718811
caapi    I-Antidepressant102718811
"    O
,    O
and    O
to    O
the    O
brew    O
prepared    O
from    O
it    O
.    O

Intranasal    O
esketamine    B-Antidepressant102718811
,    O
an    O
enantiomer    O
of    O
ketamine    O
,    O
is    O
in    O
the    O
final    O
stages    O
of    O
development    O
for    O
depression    O
.    O

NMDA    O
receptor    O
antagonists    O
like    O
ketamine    O
,    O
esketamine    B-Antidepressant102718811
(    O
JNJ-54135419    O
)    O
,    O
rapastinel    O
(    O
GLYX-13    O
)    O
,    O
apimostinel    O
(    O
NRX-1074    O
)    O
,    O
4-chlorokynurenine    O
(    O
AV-101    O
)    O
,    O
traxoprodil    O
(    O
CP-101606    O
)    O
,    O
rislenemdaz    O
(    O
CERC-301    O
,    O
MK-0657    O
)    O
,    O
nitrous    O
oxide    O
,    O
and    O
others    O

ketamine    O
(    O
dissociative    O
)    O
and    O
its    O
stereoisomer    O
esketamine    B-Antidepressant102718811

2C-T-19    B-Antidepressant102718811
or    O
2,5-dimethoxy-4-butylthiophenethylamine    O
is    O
a    O
psychedelic    O
phenethylamine    O
of    O
the    O
2C    O
family    O
.    O

A    O
major    O
constituent    O
chemical    O
,    O
hyperforin    B-Antidepressant102718811
,    O
may    O
be    O
useful    O
for    O
treatment    O
of    O
alcoholism    O
,    O
although    O
dosage    O
,    O
safety    O
and    O
efficacy    O
have    O
not    O
been    O
studied    O
.    O

GABA    O
reuptake    O
inhibitors    O
:    O
deramciclane    O
,    O
hyperforin    B-Antidepressant102718811
,    O
tiagabine    O
.    O

Two    O
of    O
the    O
primary    O
active    O
constituents    O
responsible    O
for    O
the    O
antidepressant    O
and    O
anxiolytic    O
benefits    O
of    O
"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
,    O
also    O
known    O
as    O
St.    O
John    O
's    O
Wort    O
,    O
are    O
hyperforin    B-Antidepressant102718811
and    O
adhyperforin    O
.    O

Some    O
chemicals    O
found    O
in    O
trace    O
amounts    O
in    O
food    O
,    O
and    O
some    O
dietary    O
supplements    O
,    O
also    O
have    O
been    O
shown    O
in    O
inhibit    O
5-LOX    O
,    O
such    O
as    O
baicalein    O
,    O
caffeic    O
acid    O
,    O
curcumin    O
,    O
hyperforin    B-Antidepressant102718811
and    O
St    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
.    O

Pivhydrazine    B-Antidepressant102718811
(    O
trade    O
name    O
Tersavid    B-Antidepressant102718811
)    O
,    O
also    O
known    O
as    O
pivalylbenzhydrazine    B-Antidepressant102718811
and    O
pivazide    B-Antidepressant102718811
,    O
is    O
an    O
irreversible    O
and    O
non    O
-    O
selective    O
monoamine    O
oxidase    O
inhibitor    O
(    O
MAOI    O
)    O
of    O
the    O
hydrazine    O
family    O
.    O

NGD-4715    B-Antidepressant102718811

Collections    O
include    O
acacia    O
,    O
agave    O
,    O
aloe    O
,    O
cactus    O
,    O
echium    O
,    O
eucalyptus    O
,    O
"    O
Pelargonium    O
"    O
geranium    O
,    O
fuchsia    O
,    O
palms    O
,    O
passiflora    B-Antidepressant102718811
,    O
and    O
yucca    O
.    O

There    O
is    O
insufficient    O
evidence    O
to    O
support    O
the    O
use    O
of    O
St.    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
,    O
valerian    O
or    O
passionflower    B-Antidepressant102718811
.    O

Chrysin    O
,    O
also    O
called    O
5,7-dihydroxyflavone    O
,    O
is    O
a    O
flavone    O
found    O
in    O
honey    O
,    O
propolis    O
,    O
honeycomb    O
,    O
the    O
passion    B-Antidepressant102718811
flower    I-Antidepressant102718811
,    O
"    O
Passiflora    O
caerulea    O
"    O
and    O
"    O
Passiflora    O
incarnata    O
"    O
,    O
and    O
in    O
"    O
Oroxylum    O
indicum    O
"    O
.    O

It    O
has    O
been    O
isolated    O
from    O
honey    O
,    O
propolis    O
,    O
honeycomb    O
,    O
and    O
the    O
passion    B-Antidepressant102718811
flower    I-Antidepressant102718811
,    O
"    O
Passiflora    O
caerulea    O
"    O
and    O
"    O
Passiflora    O
incarnata    O
"    O
,    O
and    O
from    O
"    O
Oroxylum    O
indicum    O
"    O
.    O

Females    O
usually    O
lay    O
yellow    O
eggs    O
singly    O
on    O
shoots    O
of    O
various    O
host    O
plants    O
,    O
mainly    O
"    O
Passiflora    B-Antidepressant102718811
"    O
species    O
,    O
of    O
which    O
caterpillars    O
primarily    O
feed    O
.    O

In    O
"    O
Passiflora    B-Antidepressant102718811
"    O
,    O
the    O
tendrils    O
develop    O
from    O
the    O
axillary    O
bud    O
.    O

State    O
wildflower    O
-    O
passion    B-Antidepressant102718811
flower    I-Antidepressant102718811
.    O

The    O
larvae    O
of    O
these    O
butterflies    O
eat    O
passion    B-Antidepressant102718811
flower    I-Antidepressant102718811
vines    O
(    O
Passifloraceae    O
)    O
.    O

|    O
"    O
Passiflora    B-Antidepressant102718811
morifolia    O
"    O

Passiflora    O
bryonioides    O
,    O
the    O
cupped    O
passionflower    O
,    O
is    O
a    O
plant    O
in    O
the    O
genus    O
"    O
Passiflora    B-Antidepressant102718811
"    O
,    O
family    O
Passifloraceae    O
.    O

It    O
is    O
also    O
found    O
in    O
passion    O
flowers    O
(    O
"    O
Passiflora    B-Antidepressant102718811
sp    O
.    O
"    O
)    O
.    O

The    O
larvae    O
feed    O
on    O
plants    O
from    O
the    O
genus    O
"    O
Granadilla    B-Antidepressant102718811
"    O
.    O

Passiflora    O
ambigua    O
is    O
a    O
species    O
of    O
"    O
Passiflora    B-Antidepressant102718811
"    O
from    O
Belize    O
,    O
Costa    O
Rica    O
,    O
and    O
Colombia    O
.    O

Passiflora    O
cinnabarina    O
is    O
a    O
species    O
of    O
"    O
Passiflora    B-Antidepressant102718811
"    O
from    O
Australia    O
.    O

Passiflora    O
cincinnata    O
is    O
a    O
species    O
of    O
Passiflora    B-Antidepressant102718811
from    O
Brazil    O
.    O

Passiflora    O
membranacea    O
is    O
a    O
species    O
of    O
"    O
Passiflora    B-Antidepressant102718811
"    O
from    O
Costa    O
Rica    O
,    O
Guatemala    O
,    O
and    O
El    O
Salvador    O
.    O

Passiflora    O
serratifolia    O
is    O
a    O
species    O
of    O
"    O
Passiflora    B-Antidepressant102718811
"    O
from    O
Suriname    O
.    O

Passiflora    O
manicata    O
is    O
a    O
species    O
of    O
Passiflora    B-Antidepressant102718811
from    O
Colombia    O
and    O
Ecuador    O
.    O

Medicinal    O
herbs    O
are    O
common    O
in    O
the    O
whole    O
country    O
;    O
among    O
the    O
most    O
popular    O
are    O
:    O
chamomile    O
,    O
lanceleaf    O
,    O
"    O
boldo    O
"    O
,    O
"    O
poleo    O
"    O
,    O
"    O
peperina    O
"    O
,    O
"    O
carqueja    O
"    O
,    O
thyme    O
,    O
"    O
canchalagua    O
"    O
,    O
rue    O
(    O
"    O
macho    O
"    O
and    O
"    O
hembra    O
"    O
,    O
that    O
is    O
,    O
"    O
male    O
"    O
and    O
"    O
female    O
"    O
)    O
,    O
mallow    O
,    O
rosemary    O
,    O
passion    B-Antidepressant102718811
flower    I-Antidepressant102718811
,    O
"    O
bira    O
bira    O
"    O
,    O
"    O
palán    O
palán    O
"    O
,    O
"    O
muña    O
muña    O
"    O
,    O
to    O
mention    O
only    O
the    O
main    O
ones    O
.    O

Passion    B-Antidepressant102718811
flower    I-Antidepressant102718811

Old    O
wisteria    O
trees    O
are    O
a    O
feature    O
of    O
the    O
verandah    O
,    O
together    O
with    O
passion    B-Antidepressant102718811
flower    I-Antidepressant102718811
and    O
banksia    O
roses    O
.    O

Passiflora    O
foetida    O
(    O
common    O
names    O
:    O
wild    O
maracuja    O
,    O
bush    O
passion    O
fruit    O
,    O
marya    O
-    O
marya    O
,    O
wild    O
water    O
lemon    O
,    O
stinking    O
passionflower    O
,    O
love    O
-    O
in    O
-    O
a    O
-    O
mist    O
or    O
running    O
pop    O
)    O
is    O
a    O
species    O
of    O
passion    B-Antidepressant102718811
flower    I-Antidepressant102718811
that    O
is    O
native    O
to    O
the    O
southwestern    O
United    O
States    O
(    O
southern    O
Texas    O
and    O
Arizona    O
)    O
,    O
Mexico    O
,    O
the    O
Caribbean    O
,    O
Central    O
America    O
,    O
and    O
much    O
of    O
South    O
America    O
.    O

Viloxazine    B-Antidepressant102718811
(    O
trade    O
names    O
Vivalan    B-Antidepressant102718811
,    O
Emovit    B-Antidepressant102718811
,    O
Vivarint    B-Antidepressant102718811
and    O
Vicilan    B-Antidepressant102718811
)    O
is    O
a    O
morpholine    O
derivative    O
and    O
is    O
a    O
selective    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
NRI    O
)    O
.    O

Viloxazine    B-Antidepressant102718811
(    O
Vivalan    O
)    O

Healy    O
allegedly    O
encountered    O
ghost    O
writing    O
involving    O
Wyeth    O
's    O
SNRI    O
Effexor    B-Antidepressant102718811
.    O

As    O
of    O
2013    O
,    O
the    O
10    O
most    O
prescribed    O
psychiatric    O
drugs    O
by    O
number    O
of    O
prescriptions    O
were    O
alprazolam    O
,    O
sertraline    O
,    O
citalopram    B-Antidepressant102718811
,    O
fluoxetine    O
,    O
lorazepam    O
,    O
trazodone    O
,    O
escitalopram    B-Antidepressant102718811
,    O
duloxetine    O
,    O
bupropion    B-Antidepressant102718811
XL    I-Antidepressant102718811
,    O
and    O
venlafaxine    B-Antidepressant102718811
XR    I-Antidepressant102718811
.    O

Venlafaxine    B-Antidepressant102718811
(    O
Effexor    O
)    O
,    O
SNRI    O

Venlafaxine    B-Antidepressant102718811
(    O
Effexor    O
)    O
may    O
be    O
moderately    O
more    O
effective    O
than    O
SSRIs    O
;    O
however    O
,    O
it    O
is    O
not    O
recommended    O
as    O
a    O
first    O
-    O
line    O
treatment    O
because    O
of    O
the    O
higher    O
rate    O
of    O
side    O
effects    O
,    O
and    O
its    O
use    O
is    O
specifically    O
discouraged    O
in    O
children    O
and    O
adolescents    O
.    O

Venlafaxine    B-Antidepressant102718811
/    O
quetiapine    O
?    O

The    O
following    O
list    O
shows    O
the    O
rates    O
of    O
adverse    O
symptoms    O
seen    O
in    O
people    O
taking    O
venlafaxine    B-Antidepressant102718811
.    O

Mirtazapine    O
in    O
combination    O
with    O
an    O
SSRI    O
,    O
,    O
or    O
TCA    O
as    O
an    O
augmentation    O
strategy    O
is    O
considered    O
to    O
be    O
relatively    O
safe    O
and    O
is    O
often    O
employed    O
therapeutically    O
,    O
with    O
a    O
combination    O
of    O
venlafaxine    B-Antidepressant102718811
and    O
mirtazapine    O
,    O
sometimes    O
referred    O
to    O
as    O
"    O
California    O
rocket    O
fuel    O
"    O
.    O

The    O
rate    O
of    O
withdrawal    O
symptoms    O
in    O
young    O
people    O
may    O
be    O
higher    O
with    O
paroxetine    O
and    O
venlafaxine    B-Antidepressant102718811
than    O
other    O
SSRIs    O
and    O
SNRIs    O
.    O

Comparative    O
efficacy    O
of    O
paroxetine    O
is    O
equivalent    O
to    O
that    O
of    O
clomipramine    O
and    O
venlafaxine    B-Antidepressant102718811
.    O

Tramadol    O
is    O
structurally    O
closer    O
to    O
venlafaxine    B-Antidepressant102718811
than    O
to    O
codeine    O
and    O
delivers    O
analgesia    O
by    O
not    O
only    O
delivering    O
"    O
opioid    O
-    O
like    O
"    O
effects    O
(    O
through    O
mild    O
agonism    O
of    O
the    O
mu    O
receptor    O
)    O
but    O
also    O
by    O
acting    O
as    O
a    O
weak    O
but    O
fast    O
-    O
acting    O
serotonin    O
releasing    O
agent    O
and    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
.    O

Commonly    O
used    O
ones    O
are    O
venlafaxine    B-Antidepressant102718811
,    O
nefazadone    O
,    O
bupropion    B-Antidepressant102718811
,    O
mirtazapine    B-Antidepressant102718811
and    O
trazodone    O
.    O

Level    O
four    O
consisted    O
of    O
the    O
monoamine    O
oxidase    O
inhibitor    O
tranylcypromine    O
or    O
a    O
combination    O
of    O
venlafaxine    B-Antidepressant102718811
and    O
mirtazapine    B-Antidepressant102718811
.    O

Venlafaxine    B-Antidepressant102718811

Lortalamine    B-Antidepressant102718811
(    O
LM-1404    O
)    O

4-MTA    B-Antidepressant102718811

a-Methyl-4-(methylthio)phenethylamine    B-Antidepressant102718811

Flatliner    O
,    O
psychoactive    O
drug    O
4-MTA    B-Antidepressant102718811

Lofepramine    B-Antidepressant102718811
,    O
sold    O
under    O
the    O
brand    O
names    O
Gamanil    B-Antidepressant102718811
,    O
Lomont    B-Antidepressant102718811
,    O
and    O
Tymelyt    B-Antidepressant102718811
among    O
others    O
,    O
is    O
a    O
tricyclic    O
antidepressant    O
(    O
TCA    O
)    O
which    O
is    O
used    O
to    O
treat    O
depression    O
.    O

Amitriptyline    O
,    O
imipramine    O
,    O
lofepramine    B-Antidepressant102718811
and    O
clomipramine    O
are    O
tricyclic    O
antidepressants    O
and    O
tertiary    O
amines    O
.    O

ATC-0175    B-Antidepressant102718811

There    O
is    O
tentative    O
evidence    O
for    O
the    O
medication    O
flupentixol    B-Antidepressant102718811
;    O
however    O
,    O
greater    O
study    O
is    O
required    O
before    O
it    O
can    O
be    O
recommended    O
.    O

Between    O
March    O
and    O
April    O
1991    O
,    O
Charnley    O
experimented    O
with    O
varying    O
dosages    O
of    O
his    O
medication    O
-    O
Depixol    B-Antidepressant102718811
and    O
Tryptisol    O
-    O
painting    O
a    O
self    O
-    O
portrait    O
each    O
day    O
that    O
reflected    O
how    O
his    O
concept    O
of    O
'    O
self    O
'    O
changed    O
with    O
the    O
illness    O
.    O

Flupenthixol    B-Antidepressant102718811
(    O
Fluanxol    O
)    O

Amixetrine    B-Antidepressant102718811
(    O
INN    O
)    O
(    O
brand    O
name    O
Somagest    B-Antidepressant102718811
;    O
developmental    O
code    O
name    O
CERM-898    B-Antidepressant102718811
)    O
is    O
a    O
drug    O
that    O
was    O
formerly    O
marketed    O
in    O
France    O
but    O
is    O
now    O
no    O
longer    O
sold    O
.    O

etryptamine    B-Antidepressant102718811
(    O
INN    O
)    O

#    O
Etryptamine    B-Antidepressant102718811

"    O
United    O
States    O
v.    O
Forbes    O
"    O
,    O
806    O
F.    O
Supp    O
.    O
232    O
(    O
D.    O
Colo.    O
1992    O
)    O
,    O
a    O
Colorado    O
district    O
court    O
case    O
,    O
considered    O
the    O
question    O
of    O
whether    O
the    O
drug    O
alphaethyltryptamine    B-Antidepressant102718811
(    O
AET    O
)    O
was    O
a    O
controlled    O
substance    O
analogue    O
in    O
the    O
USA    O
.    O

etryptamine    B-Antidepressant102718811
(    O
αET    O
)    O

Toloxatone    B-Antidepressant102718811
(    O
Humoryl    O
)    O

:    O
N06AG03    O
Toloxatone    B-Antidepressant102718811

Almoxatone    B-Antidepressant102718811
(    O
MD-780,236    B-Antidepressant102718811
)    O
is    O
a    O
selective    O
and    O
reversible    O
inhibitor    O
of    O
MAO    O
-    O
B.    O
It    O
was    O
patented    O
as    O
an    O
antidepressant    O
and    O
antiparkinsonian    O
agent    O
but    O
was    O
never    O
marketed    O
.    O

;    O
monomethylhydrazine    B-Antidepressant102718811
:    O
CH3NHNH2    O

The    O
OAMS    O
had    O
16    O
small    O
,    O
fixed    O
-    O
position    O
,    O
fixed    O
-    O
thrust    O
rocket    O
engines    O
which    O
burned    O
hypergolic    O
propellants    O
(    O
monomethylhydrazine    B-Antidepressant102718811
fuel    O
using    O
nitrogen    O
tetroxide    O
as    O
oxidizer    O
)    O
fed    O
under    O
pressure    O
from    O
a    O
pair    O
of    O
tanks    O
located    O
in    O
the    O
aft    O
Equipment    O
Module    O
.    O

SuperDracos    O
use    O
a    O
storable    O
propellant    O
combination    O
of    O
monomethyl    B-Antidepressant102718811
hydrazine    I-Antidepressant102718811
(    O
MMH    O
)    O
fuel    O
and    O
nitrogen    O
tetroxide    O
oxidizer    O
(    O
NTO    O
)    O
,    O
the    O
same    O
propellants    O
used    O
in    O
the    O
much    O
smaller    O
Draco    O
thrusters    O
used    O
for    O
attitude    O
control    O
and    O
maneuvering    O
on    O
the    O
first    O
-    O
generation    O
Dragon    O
spacecraft    O
.    O

The    O
spacecraft    O
propulsion    O
system    O
consisted    O
of    O
a    O
monopropellant    O
hydrazine    O
system    O
for    O
attitude    O
control    O
and    O
a    O
bipropellant    O
nitrogen    O
tetroxide    O
and    O
monomethyl    B-Antidepressant102718811
hydrazine    I-Antidepressant102718811
system    O
for    O
the    O
maneuvers    O
in    O
space    O
.    O

Monomethylhydrazine    B-Antidepressant102718811
,    O
a    O
chemical    O
with    O
the    O
formula    O
CH3N2H3    O
.    O

Research    O
has    O
established    O
this    O
species    O
contains    O
monomethylhydrazine    B-Antidepressant102718811
,    O
which    O
can    O
cause    O
severe    O
sporadic    O
intoxications    O
,    O
and    O
may    O
be    O
carcinogenic    O
.    O

The    O
line    O
carried    O
monomethyl    B-Antidepressant102718811
hydrazine    I-Antidepressant102718811
(    O
MMH    O
)    O
propellant    O
,    O
one    O
of    O
two    O
chemicals    O
(    O
the    O
other    O
is    O
an    O
oxidizer    O
,    O
nitrogen    O
tetroxide    O
)    O
used    O
to    O
ignite    O
the    O
OMS    O
engines    O
.    O

"    O
Stage    O
4    O
:    O
"    O
Liquid    O
MMH    B-Antidepressant102718811
+    O
MON-3    O

European    O
space    O
companies    O
have    O
researched    O
using    O
light    O
hydrocarbons    O
with    O
liquid    O
oxygen    O
as    O
a    O
relatively    O
high    O
performing    O
liquid    O
rocket    O
propellant    O
combination    O
that    O
would    O
also    O
be    O
less    O
toxic    O
than    O
the    O
commonly    O
used    O
MMH    O
/    O
NTO    O
(    O
monomethylhydrazine    B-Antidepressant102718811
/    O
nitrogen    O
tetroxide    O
)    O
.    O

ciclindole    B-Antidepressant102718811
(    O
INN    O
)    O

mofegiline    B-Antidepressant102718811
(    O
INN    O
)    O

para    O
"-    O
Methoxyethylamphetamine    O
("'PMEA    B-Antidepressant102718811
)    O
,    O
is    O
a    O
stimulant    O
drug    O
related    O
to    O
PMA    B-Antidepressant102718811
.    O

Edivoxetine    B-Antidepressant102718811
(    O
INN    O
;    O
code    O
name    O
LY-2216684    B-Antidepressant102718811
)    O
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
selective    O
norepinephrine    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
and    O
was    O
under    O
development    O
by    O
Eli    O
Lilly    O
for    O
attention    O
-    O
deficit    O
disorder    O
(    O
ADD    O
)    O
and    O
as    O
an    O
antidepressant    O
treatment    O
.    O

Phenoxypropazine    B-Antidepressant102718811
(    O
trade    O
name    O
Drazine    B-Antidepressant102718811
)    O
is    O
an    O
irreversible    O
and    O
non    O
-    O
selective    O
monoamine    O
oxidase    O
inhibitor    O
(    O
MAOI    O
)    O
of    O
the    O
hydrazine    O
family    O
.    O

methoxymethamphetamine    O
or    O
"    O
'    O
MMMA    O
)    O
,    O
which    O
is    O
most    O
closely    O
related    O
to    O
3-methoxyamphetamine    O
and    O
PMMA    B-Antidepressant102718811
and    O
shares    O
similar    O
monoamine    O
releasing    O
effects    O
,    O
although    O
its    O
effects    O
have    O
not    O
been    O
studied    O
so    O
extensively    O
as    O
other    O
related    O
drugs    O
.    O

Methyl-MA    B-Antidepressant102718811

#    O
PMA    B-Antidepressant102718811
&    O
PMMA    B-Antidepressant102718811

Safrazine    B-Antidepressant102718811
(    O
Safra    B-Antidepressant102718811
)    O
is    O
a    O
non    O
-    O
selective    O
,    O
irreversible    O
monoamine    O
oxidase    O
inhibitor    O
(    O
MAOI    O
)    O
of    O
the    O
hydrazine    O
class    O
that    O
was    O
introduced    O
as    O
an    O
antidepressant    O
in    O
the    O
1960s    O
,    O
but    O
has    O
since    O
been    O
discontinued    O
.    O

dibenzepin    B-Antidepressant102718811
(    O
INN    O
)    O

:    O
N06AX07    O
Minaprine    B-Antidepressant102718811

minaprine    B-Antidepressant102718811
(    O
INN    O
)    O

Talsupram    B-Antidepressant102718811
(    O
Lu    O
5    O
-    O
005    O
)    O

Higher    O
doses    O
of    O
the    O
patch    O
and    O
oral    O
formulations    O
,    O
whether    O
in    O
combination    O
with    O
the    O
older    O
non    O
-    O
selective    O
MAOIs    O
or    O
in    O
combination    O
with    O
the    O
reversible    O
MAO    O
-    O
A    O
inhibitor    O
moclobemide    B-Antidepressant102718811
,    O
require    O
a    O
low    O
tyramine    O
diet    O
.    O

moclobemide    B-Antidepressant102718811

:    O
moclobemide    B-Antidepressant102718811
(    O
antidepressant    O
)    O

Moclobemide    B-Antidepressant102718811
.    O
Moclobemide    O
is    O
advised    O
not    O
to    O
be    O
started    O
until    O
at    O
least    O
one    O
week    O
after    O
treatment    O
with    O
TCAs    O
is    O
discontinued    O
.    O

Compared    O
to    O
the    O
reversible    O
MAOI    O
antidepressant    O
drug    O
moclobemide    B-Antidepressant102718811
,    O
significantly    O
more    O
impairment    O
of    O
vigilance    O
occurs    O
with    O
trazodone    O
.    O

However    O
,    O
evidence    O
indicates    O
that    O
harmala    O
alkaloids    O
act    O
only    O
on    O
MAO    O
-    O
A    O
,    O
in    O
a    O
reversible    O
way    O
similar    O
to    O
moclobemide    B-Antidepressant102718811
(    O
an    O
antidepressant    O
that    O
does    O
not    O
require    O
dietary    O
restrictions    O
)    O
.    O

File    O
:    O
Peganum    O
harmala    O
Baikonur    O
09.jpg|Loculicidal    O
dehiscence    O
in    O
"    O
Peganum    B-Antidepressant102718811
harmala    I-Antidepressant102718811
"    O

"    O
Peganum    B-Antidepressant102718811
harmala    I-Antidepressant102718811
"    O

Syrian    O
rue    O
,    O
"    O
Peganum    B-Antidepressant102718811
harmala    I-Antidepressant102718811
"    O
,    O
a    O
plant    O
in    O
the    O
Nitrariaceae    O
family    O

For    O
example    O
,    O
seeds    O
of    O
the    O
Syrian    B-Antidepressant102718811
rue    I-Antidepressant102718811
plant    O
can    O
be    O
used    O
as    O
a    O
substitute    O
for    O
the    O
ayahuasca    O
vine    O
,    O
and    O
the    O
DMT    O
-    O
rich    O
"    O
Mimosa    O
hostilis    O
"    O
is    O
used    O
in    O
place    O
of    O
"    O
chacruna    O
"    O
.    O

Harmal    B-Antidepressant102718811
(    O
"    O
Peganum    O
harmala    O
"    O
,    O
Syrian    O
rue    O
)    O
–    O
seeds    O

Dried    O
capsules    O
of    O
Esfand    B-Antidepressant102718811
(    O
Peganum    O
harmala)(known    O
in    O
Persian    O
as    O
اسپند    O
espænd    O
or    O
اسفنددانه    O
esfænd    O
-    O
dāneh    O
)    O
mixed    O
with    O
other    O
ingredients    O
are    O
placed    O
onto    O
red    O
hot    O
charcoal    O
,    O
where    O
they    O
explode    O
with    O
little    O
popping    O
noises    O
,    O
releasing    O
a    O
fragrant    O
smoke    O
that    O
is    O
wafted    O
around    O
the    O
head    O
of    O
those    O
afflicted    O
by    O
or    O
exposed    O
to    O
the    O
gaze    O
of    O
strangers    O
.    O

Many    O
substituted    O
phenethylamines    O
are    O
psychoactive    O
drugs    O
which    O
belong    O
to    O
a    O
variety    O
of    O
different    O
drug    O
classes    O
,    O
including    O
central    O
nervous    O
system    O
stimulants    O
(    O
e.g.    O
,    O
amphetamine    O
)    O
,    O
hallucinogens    O
(    O
e.g.    O
,    O
dl-2,5-dimethoxy-4-methylamphetamine    O
DOM    O
)    O
,    O
entactogens    O
(    O
e.g.    O
,    O
3,4-methylenedioxyamphetamine    O
MDA    O
)    O
,    O
appetite    O
suppressants    O
(    O
e.g.    O
phentermine    O
)    O
,    O
nasal    O
decongestants    O
and    O
bronchodilators    O
(    O
e.g.    O
,    O
levomethamphetamine    O
and    O
pseudoephedrine    O
)    O
,    O
antidepressants    O
(    O
e.g.    O
bupropion    B-Antidepressant102718811
and    O
phenelzine    O
)    O
,    O
antiparkinson    O
agents    O
(    O
e.g.    O
,    O
selegiline    B-Antidepressant102718811
)    O
,    O
and    O
vasopressors    O
(    O
e.g.    O
,    O
ephedrine    O
)    O
,    O
among    O
others    O
.    O

A    O
MAO    O
-    O
B    O
inhibitor    O
such    O
as    O
selegiline    B-Antidepressant102718811
or    O
rasagiline    O
can    O
prevent    O
this    O
from    O
happening    O
.    O

Omigapil    O
was    O
originally    O
developed    O
as    O
a    O
structurally    O
similar    O
molecule    O
to    O
selegiline    B-Antidepressant102718811
(    O
L    O
-    O
deprenyl    O
)    O
,    O
a    O
monoamine    O
oxidase    O
inhibitor    O
(    O
MAO    O
)    O
blocking    O
the    O
enzyme    O
MAO    O
type    O
B    O
,    O
yet    O
omigapil    O
inhibit    O
neither    O
type    O
of    O
MAO    O
.    O

MAO    O
-    O
B    O
inhibitors    O
(    O
safinamide    O
,    O
selegiline    B-Antidepressant102718811
and    O
rasagiline    O
)    O
increase    O
the    O
amount    O
of    O
dopamine    O
in    O
the    O
basal    O
ganglia    O
by    O
inhibiting    O
the    O
activity    O
of    O
monoamine    O
oxidase    O
B    O
(    O
MAO    O
-    O
B    O
)    O
,    O
an    O
enzyme    O
which    O
breaks    O
down    O
dopamine    O
.    O

Agents    O
currently    O
under    O
investigation    O
include    O
anti    O
-    O
apoptotics    O
(    O
omigapil    O
,    O
CEP-1347    O
)    O
,    O
antiglutamatergics    O
,    O
monoamine    O
oxidase    O
inhibitors    O
(    O
selegiline    B-Antidepressant102718811
,    O
rasagiline    O
)    O
,    O
promitochondrials    O
(    O
coenzyme    O
Q10    O
,    O
creatine    O
)    O
,    O
calcium    O
channel    O
blockers    O
(    O
isradipine    O
)    O
and    O
growth    O
factors    O
(    O
GDNF    O
)    O
.    O

Examples    O
of    O
substituted    O
amphetamines    O
are    O
amphetamine    O
(    O
itself    O
)    O
,    O
methamphetamine    O
,    O
ephedrine    O
,    O
cathinone    O
,    O
phentermine    O
,    O
mephentermine    O
,    O
bupropion    B-Antidepressant102718811
,    O
methoxyphenamine    O
,    O
selegiline    B-Antidepressant102718811
,    O
amfepramone    O
,    O
pyrovalerone    O
,    O
MDMA    O
(    O
ecstasy    O
)    O
,    O
and    O
DOM    O
(    O
STP    O
)    O
.    O

A    O
variety    O
of    O
prodrugs    O
of    O
amphetamine    O
and/or    O
methamphetamine    O
exist    O
,    O
and    O
include    O
amfecloral    O
,    O
amphetaminil    O
,    O
benzphetamine    O
,    O
clobenzorex    O
,    O
D-deprenyl    B-Antidepressant102718811
,    O
dimethylamphetamine    O
,    O
ethylamphetamine    O
,    O
fencamine    O
,    O
fenethylline    O
,    O
fenproporex    O
,    O
furfenorex    O
,    O
lisdexamfetamine    O
,    O
mefenorex    O
,    O
mesocarb    O
,    O
prenylamine    O
,    O
selegiline    B-Antidepressant102718811
,    O
and    O
tranylcypromine    O
.    O

Some    O
of    O
these    O
medicines    O
include    O
selegiline    B-Antidepressant102718811
,    O
amantadine    O
,    O
entacapone    O
,    O
dopamine    O
agonists    O
,    O
and    O
anticholinergics    O
(    O
“    O
Movement    O
Disorders    O
”    O
)    O
.    O

Nootropics    O
may    O
enhance    O
cognition    O
,    O
and    O
some    O
newer    O
compounds    O
like    O
NSI-189    O
,    O
9-Me    O
-    O
BC    O
,    O
Dihexa    O
,    O
Selegiline    B-Antidepressant102718811
,    O
and    O
Modafinil    O
can    O
produce    O
beneficial    O
cognitive    O
enhancing    O
effects    O
.    O

selegiline    B-Antidepressant102718811
(    O
monoamine    O
oxidase    O
inhibitor    O
)    O

The    O
amino    O
acid    O
tryptophan    O
is    O
converted    O
into    O
5-hydroxytryptophan    B-Antidepressant102718811
(    O
5-HTP    O
)    O
which    O
is    O
subsequently    O
converted    O
into    O
the    O
neurotransmitter    O
serotonin    O
.    O

Amine    O
Precursor    O
Uptake    O
-    O
for    O
high    O
uptake    O
of    O
amine    O
precursors    O
including    O
5-hydroxytryptophan    O
(    O
5-HTP    B-Antidepressant102718811
)    O
and    O
dihydroxyphenylalanine    O
(    O
DOPA    O
)    O
.    O

Treatment    O
of    O
THB    O
deficiencies    O
consists    O
of    O
THB    O
supplementation    O
(    O
2–20    O
mg    O
/    O
kg    O
per    O
day    O
)    O
or    O
diet    O
to    O
control    O
blood    O
phenylalanine    O
concentration    O
and    O
replacement    O
therapy    O
with    O
neurotransmitters    O
precursors    O
(    O
L    O
-    O
DOPA    O
and    O
5-HTP    B-Antidepressant102718811
)    O
and    O
supplements    O
of    O
folinic    O
acid    O
in    O
DHPR    O
deficiency    O
.    O

The    O
seeds    O
of    O
the    O
plant    O
are    O
used    O
as    O
a    O
herbal    O
supplement    O
for    O
their    O
5-hydroxytryptophan    B-Antidepressant102718811
(    O
5-HTP    O
)    O
content    O
.    O

Velvet    B-Antidepressant102718811
bean    I-Antidepressant102718811
(    O
"    O
M.    O
pruriens    O
"    O
)    O
is    O
one    O
of    O
the    O
most    O
important    O
sources    O
of    O
L    O
-    O
dopa    O
,    O
a    O
common    O
component    O
of    O
nootropics    O
(    O
"    O
smart    O
drugs    O
"    O
)    O
;    O
it    O
also    O
contains    O
serotonin    O
,    O
5-HTP    B-Antidepressant102718811
,    O
nicotine    O
,    O
and    O
some    O
decidedly    O
psychoactive    O
compounds    O
(    O
see    O
below    O
)    O
.    O

Tryptophan    O
and    O
5-hydroxy-tryptophan    B-Antidepressant102718811
,    O
for    O
instance    O
,    O
can    O
be    O
used    O
to    O
help    O
the    O
body    O
replenish    O
serotonin    O
levels    O
in    O
the    O
brain    O
after    O
the    O
use    O
of    O
MDMA    O
,    O
and    O
vitamin    O
supplements    O
are    O
appropriate    O
for    O
users    O
of    O
stimulants    O
such    O
as    O
amphetamine    O
.    O

naranol    B-Antidepressant102718811
(    O
INN    O
)    O

2C-T-8    B-Antidepressant102718811
is    O
a    O
psychedelic    O
phenethylamine    O
of    O
the    O
2C    O
family    O
.    O

Indalpine    B-Antidepressant102718811

Indalpine    B-Antidepressant102718811
(    O
Upstene    O
)    O
and    O
zimelidine    O
(    O
Normud    O
,    O
Zelmid    O
)    O
were    O
also    O
formerly    O
used    O
as    O
antidepressants    O
,    O
but    O
were    O
withdrawn    O
from    O
the    O
market    O
.    O

mebanazine    B-Antidepressant102718811
(    O
INN    O
)    O

On    O
Friday    O
,    O
January    O
06    O
,    O
2017    O
Representative    O
Jacobs    O
filed    O
Bill    O
HB    O
183    O
in    O
The    O
Florida    O
House    O
of    O
Representatives    O
which    O
,    O
if    O
passed    O
and    O
signed    O
into    O
law    O
,    O
would    O
effectively    O
schedule    O
kratom    B-Antidepressant102718811
as    O
a    O
controlled    O
substance    O
.    O

The    O
drugs    O
involved    O
range    O
from    O
the    O
traditional    O
,    O
kratom    B-Antidepressant102718811
,    O
to    O
ya    O
ba    O
,    O
opium    O
from    O
Myanmar    O
,    O
and    O
local    O
herbal    O
medicines    O
.    O

Mitragyna    B-Antidepressant102718811
speciosa    I-Antidepressant102718811
(    O
kratom    O
)    O
indole    O
derivatives    O
:    O

Carbenzide    B-Antidepressant102718811
(    O
INN    O
)    O
,    O
also    O
known    O
as    O
carbazic    B-Antidepressant102718811
acid    I-Antidepressant102718811
,    O
is    O
a    O
hydrazine    O
derivative    O
monoamine    O
oxidase    O
inhibitor    O
(    O
MAOI    O
)    O
antidepressant    O
which    O
was    O
never    O
marketed    O
.    O

N,alpha-diethylphenylethylamine    B-Antidepressant102718811

In    O
Mexico    O
,    O
where    O
it    O
is    O
only    O
known    O
from    O
the    O
north    O
and    O
central    O
part    O
of    O
the    O
country    O
,    O
it    O
has    O
been    O
usually    O
collected    O
in    O
arid    O
and    O
semiarid    O
areas    O
,    O
on    O
coastal    O
dunes    O
,    O
found    O
from    O
sea    O
level    O
up    O
to    O
high    O
.    O
The    O
mushroom    O
has    O
been    O
associated    O
with    O
the    O
quick    O
-    O
growing    O
evergreen    O
tree    O
"    O
Schinus    B-Antidepressant102718811
molle    I-Antidepressant102718811
"    O
,    O
as    O
well    O
as    O
"    O
Lycium    O
brevipes    O
"    O
,    O
"    O
Solanum    O
hindsianum    O
"    O
,    O
"    O
Salicornia    O
subterminalis    O
"    O
,    O
"    O
Atriplex    O
linearis    O
"    O
,    O
"    O
Quercus    O
agrifolia    O
"    O
and    O
"    O
Opuntia    O
"    O
species    O
,    O
in    O
coastal    O
dunes    O
.    O

The    O
native    O
plants    O
are    O
centuryplant    O
,    O
cholla    O
,    O
pickly    O
pear    O
,    O
golden    O
barrel    O
,    O
fencepost    O
cactus    O
,    O
billberry    O
cactus    O
,    O
Mexican    O
creeping    O
zinnia    O
,    O
creosote    O
bush    O
,    O
pepicha    O
,    O
creeping    O
false    O
holly    O
,    O
tule    O
,    O
reed    O
,    O
barrel    O
cactus    O
,    O
fern    O
,    O
trees    O
as    O
kidneywood    O
tree    O
,    O
mesquite    O
,    O
netleaf    O
oak    O
,    O
tepozán    O
,    O
needle    O
bush    O
,    O
fruit    O
trees    O
as    O
tejocote    O
,    O
capulin    O
,    O
white    O
sapote    O
and    O
foreign    O
trees    O
as    O
pirul    B-Antidepressant102718811
and    O
eucalypt    O
.    O

Natural    O
vegetation    O
includes    O
jacaranda    O
,    O
guaje    O
,    O
mesquite    O
,    O
white    O
sapote    O
and    O
American    B-Antidepressant102718811
pepper    I-Antidepressant102718811
.    O

|    O
"    O
Schinus    B-Antidepressant102718811
molle    I-Antidepressant102718811
"    O

The    O
Cactus    O
and    O
Succulent    O
Garden    O
includes    O
a    O
California    B-Antidepressant102718811
pepper    I-Antidepressant102718811
tree    I-Antidepressant102718811
.    O

,    O
"    O
Prunus    O
"    O
spp    O
.    O
,    O
"    O
Schinus    B-Antidepressant102718811
molle    I-Antidepressant102718811
"    O
and    O
"    O
Quercus    O
"    O
spp    O
.    O

Selkirk    O
proved    O
resourceful    O
in    O
using    O
materials    O
that    O
he    O
found    O
on    O
the    O
island    O
:    O
he    O
forged    O
a    O
new    O
knife    O
out    O
of    O
barrel    O
hoops    O
left    O
on    O
the    O
beach    O
,    O
he    O
built    O
two    O
huts    O
out    O
of    O
pepper    B-Antidepressant102718811
trees    O
,    O
one    O
of    O
which    O
he    O
used    O
for    O
cooking    O
and    O
the    O
other    O
for    O
sleeping    O
,    O
and    O
he    O
employed    O
his    O
musket    O
to    O
hunt    O
goats    O
and    O
his    O
knife    O
to    O
clean    O
their    O
carcasses    O
.    O

As    O
more    O
rainfall    O
is    O
available    O
,    O
the    O
vegetation    O
is    O
dense    O
with    O
trees    O
such    O
as    O
conifers    O
,    O
alder    O
,    O
deciduous    O
trees    O
including    O
walnut    O
,    O
jacaranda    O
,    O
pisonia    O
,    O
"    O
Schinus    B-Antidepressant102718811
molle    I-Antidepressant102718811
"    O
,    O
quebracho    O
,    O
acacia    O
,    O
and    O
flowering    O
plants    O
such    O
as    O
orchids    O
,    O
jasmine    O
and    O
bromeliads    O
.    O

Metapramine    B-Antidepressant102718811
(    O
INN    O
)    O

Opipramol    B-Antidepressant102718811
,    O
sold    O
under    O
the    O
brand    O
name    O
Insidon    B-Antidepressant102718811
among    O
others    O
,    O
is    O
an    O
anxiolytic    O
and    O
antidepressant    O
which    O
is    O
used    O
throughout    O
Europe    O
.    O

The    O
antidepressants    O
that    O
do    O
not    O
act    O
through    O
the    O
monoamine    O
system    O
,    O
such    O
as    O
tianeptine    O
and    O
opipramol    B-Antidepressant102718811
,    O
have    O
been    O
known    O
for    O
a    O
long    O
time    O
.    O

Medifoxamine    B-Antidepressant102718811

medifoxamine    B-Antidepressant102718811
(    O
INN    O
)    O

Sulfonamides    O
(    O
such    O
as    O
sulfanilamide    O
,    O
sulfamethoxazole    O
,    O
and    O
mafenide    O
)    O
,    O
thiazolesulfone    O
,    O
methylene    O
blue    O
,    O
and    O
naphthalene    O
should    O
also    O
be    O
avoided    O
by    O
people    O
with    O
G6PD    O
deficiency    O
as    O
they    O
antagonize    O
folate    O
synthesis    O
,    O
as    O
should    O
certain    O
analgesics    O
(    O
such    O
as    O
phenazopyridine    O
and    O
acetanilide    O
)    O
and    O
a    O
few    O
non    O
-    O
sulfa    O
antibiotics    O
(    O
nalidixic    O
acid    O
,    O
nitrofurantoin    O
,    O
isoniazid    O
,    O
dapsone    O
,    O
and    O
furazolidone    B-Antidepressant102718811
)    O
.    O

furazolidone    B-Antidepressant102718811

Antibiotics    O
such    O
as    O
metronidazole    O
,    O
tinidazole    O
,    O
cephamandole    O
,    O
latamoxef    O
,    O
cefoperazone    O
,    O
cefmenoxime    O
,    O
and    O
furazolidone    B-Antidepressant102718811
,    O
cause    O
a    O
disulfiram    O
-    O
like    O
chemical    O
reaction    O
with    O
alcohol    O
by    O
inhibiting    O
its    O
breakdown    O
by    O
acetaldehyde    O
dehydrogenase    O
,    O
which    O
may    O
result    O
in    O
vomiting    O
,    O
nausea    O
,    O
and    O
shortness    O
of    O
breath    O
.    O

File    O
:    O
Hypericin    B-Antidepressant102718811

Chemical    O
structure    O
of    O
hypericin    B-Antidepressant102718811
.    O

Anthracyclines    O
,    O
hypericin    B-Antidepressant102718811
and    O
phenolic    O
lipids    O
are    O
derived    O
from    O
polyketides    O
cyclisation    O
.    O

Lactation    O
failure    O
can    O
be    O
treated    O
with    O
a    O
galactagogue    O
(    O
lactation    O
-    O
promoting    O
agent    O
)    O
such    O
as    O
a    O
D2    O
receptor    O
antagonist    O
like    O
domperidone    O
,    O
metoclopramide    O
,    O
or    O
certain    O
antipsychotics    O
like    O
chlorpromazine    O
,    O
haloperidol    O
,    O
sulpiride    B-Antidepressant102718811
,    O
or    O
risperidone    O
,    O
an    O
oxytocic    O
such    O
as    O
oxytocin    O
or    O
an    O
analogue    O
like    O
carbetocin    O
or    O
demoxytocin    O
,    O
with    O
GH    O
(    O
or    O
potentially    O
with    O
a    O
growth    O
hormone    O
secretagogue    O
,    O
alternatively    O
)    O
,    O
or    O
with    O
thyrotropin    O
-    O
releasing    O
hormone    O
(    O
TRH    O
)    O
or    O
thyroid    O
-    O
stimulating    O
hormone    O
(    O
TSH    O
)    O
.    O

That    O
research    O
project    O
also    O
produced    O
the    O
product    O
sulpiride    B-Antidepressant102718811
.    O

The    O
D2    O
receptor    O
is    O
involved    O
in    O
the    O
regulation    O
of    O
prolactin    O
secretion    O
,    O
and    O
agonists    O
of    O
the    O
receptor    O
such    O
as    O
bromocriptine    O
and    O
cabergoline    O
decrease    O
prolactin    O
levels    O
while    O
antagonists    O
of    O
the    O
receptor    O
such    O
as    O
domperidone    O
,    O
metoclopramide    O
,    O
haloperidol    O
,    O
risperidone    O
,    O
and    O
sulpiride    B-Antidepressant102718811
increase    O
prolactin    O
levels    O
.    O

Quetiapine    O
,    O
sulpiride    B-Antidepressant102718811
and    O
olanzapine    O
,    O
the    O
atypical    O
neuroleptic    O
agents    O
,    O
are    O
less    O
likely    O
to    O
yield    O
drug    O
-    O
induced    O
parkinsonism    O
and    O
tardive    O
dyskinesia    O

Sodium    O
chlorate    O
may    O
be    O
used    O
to    O
control    O
a    O
variety    O
of    O
plants    O
including    O
morning    O
glory    O
,    O
canada    O
thistle    O
,    O
johnson    O
grass    O
,    O
bamboo    O
,    O
Ragwort    O
,    O
and    O
St    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
.    O

Pill    O
sedge    O
hangs    O
on    O
in    O
its    O
only    O
known    O
Haringey    O
site    O
,    O
and    O
tiny    O
populations    O
of    O
cow    O
-    O
wheat    O
,    O
slender    O
St.    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
,    O
wood    O
anemone    O
,    O
and    O
heath    O
speedwell    O
manage    O
to    O
survive    O
,    O
though    O
they    O
seldom    O
flower    O
.    O

Plants    O
that    O
are    O
known    O
to    O
contain    O
kaempferol    O
include    O
"    O
Aloe    O
vera    O
"    O
,    O
"    O
Coccinia    O
grandis    O
"    O
,    O
"    O
Cuscuta    O
chinensis    O
"    O
,    O
"    O
Euphorbia    O
pekinensis    O
"    O
,    O
"    O
Glycine    O
max    O
"    O
,    O
"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
,    O
"    O
Moringa    O
oleifera    O
"    O
,    O
"    O
Rosmarinus    O
officinalis    O
"    O
,    O
"    O
Sambucus    O
nigra    O
"    O
,    O
and    O
"    O
Toona    O
sinensis    O
"    O
.    O
and    O
"    O
Ilex    O
"    O
.    O

"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"—    O
St    O
.    O
John    O
's    O
wort    O

There    O
is    O
insufficient    O
evidence    O
to    O
support    O
the    O
use    O
of    O
St.    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
,    O
valerian    O
or    O
passionflower    B-Antidepressant102718811
.    O

CYP3A4    O
inductors    O
,    O
for    O
example    O
rifampicin    O
and    O
possibly    O
St.    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
,    O
can    O
reduce    O
the    O
effectiveness    O
of    O
ticagrelor    O
.    O

In    O
the    O
mountains    O
gives    O
predominantly    O
the    O
typical    O
vegetation    O
of    O
Mediterranean    O
limestone    O
areas    O
characterized    O
by    O
low    O
scrub    O
(    O
thyme    O
,    O
rosemary    O
,    O
lavender    O
,    O
gorse    O
,    O
prickly    O
pears    O
,    O
agaves    O
,    O
palms    O
,    O
rock    O
roses    O
,    O
hawthorn    O
and    O
broom    O
)    O
,    O
plus    O
a    O
number    O
lower    O
plant    O
as    O
evergreens    O
,    O
vincas    O
,    O
St    B-Antidepressant102718811
John's    I-Antidepressant102718811
Wort    I-Antidepressant102718811
,    O
poppies    O
,    O
peonies    O
,    O
lilies    O
,    O
some    O
types    O
of    O
orchids    O
Mediterranean    O
...    O

and    O
5-lipoxygenase    O
inhibitors    O
,    O
like    O
zileuton    O
and    O
hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
,    O
can    O
be    O
used    O
to    O
treat    O
these    O
diseases    O
.    O

Some    O
chemicals    O
found    O
in    O
trace    O
amounts    O
in    O
food    O
,    O
and    O
some    O
dietary    O
supplements    O
,    O
also    O
have    O
been    O
shown    O
in    O
inhibit    O
5-LOX    O
,    O
such    O
as    O
baicalein    O
,    O
caffeic    O
acid    O
,    O
curcumin    O
,    O
hyperforin    B-Antidepressant102718811
and    O
St    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
.    O

Plants    O
used    O
in    O
herbalism    O
include    O
ginkgo    O
,    O
echinacea    O
,    O
feverfew    O
,    O
and    O
Saint    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
.    O

"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
L.    O

"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
,    O
the    O
type    O
species    O
of    O
the    O
genus    O
"    O
Hypericum    O
"    O
.    O

The    O
larvae    O
feed    O
on    O
the    O
flowers    O
and    O
seeds    O
of    O
"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
.    O

A    O
sprig    O
of    O
"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
harbouring    O
larva    O
.    O

Dexamethasone    O
and    O
St    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
also    O
increase    O
the    O
metabolism    O
of    O
diazepam    O
.    O

Invasive    O
weed    O
"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
in    O
the    O
Park    O
.    O

St    O
John    O
’s    O
Wort    O
(    O
"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
)    O
and    O
prickly    O
pear    O
"    O
(    O
Opuntia    O
ficus    O
-    O
indica    O
"    O
)    O
occurring    O
in    O
the    O
Mt    O
Pilot    O
Range    O
have    O
been    O
brought    O
under    O
control    O
but    O
continued    O
management    O
is    O
required    O
.    O

Evidence    O
does    O
not    O
support    O
the    O
use    O
of    O
St.    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
,    O
soy    O
,    O
vitamin    O
E    O
,    O
and    O
saffron    O
.    O

Ulipristal    O
acetate    O
is    O
likely    O
to    O
interact    O
with    O
substrates    O
of    O
CYP3A4    O
,    O
like    O
rifampicin    O
,    O
phenytoin    O
,    O
St    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
,    O
carbamazepine    O
or    O
ritonavir    O
,    O
therefore    O
concomitant    O
use    O
with    O
these    O
agents    O
is    O
not    O
recommended    O
.    O

Huffaker    O
's    O
first    O
assignment    O
was    O
the    O
control    O
of    O
Klamath    B-Antidepressant102718811
weed    I-Antidepressant102718811
,    O
particularly    O
the    O
use    O
of    O
"    O
Chrysolina    O
quadrigemina    O
"    O
.    O

The    O
larvae    O
feed    O
on    O
"    O
Chamaedaphne    O
calyculata    O
"    O
,    O
"    O
Hypericum    O
"    O
(    O
including    O
"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
)    O
,    O
"    O
Kalmia    O
"    O
and    O
"    O
Vaccinium    O
"    O
species    O
.    O

The    O
larvae    O
feed    O
on    O
"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
and    O
"    O
Prunus    O
emarginata    O
"    O
.    O

Plants    O
in    O
the    O
reserve    O
include    O
bird    O
's    O
foot    O
trefoil    O
,    O
common    O
centaury    O
,    O
rocket    O
,    O
St    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
and    O
yellow    O
-    O
wort    O

The    O
larvae    O
feed    O
on    O
"    O
Hypericum    O
adenotrichum    O
"    O
,    O
"    O
Hypericum    O
elegans    O
"    O
,    O
"    O
Hypericum    O
hircinum    O
"    O
,    O
"    O
Hypericum    O
hirsutum    O
"    O
,    O
"    O
Hypericum    O
humifusum    O
"    O
,    O
"    O
Hypericum    O
maculatum    O
"    O
,    O
"    O
Hypericum    O
montanum    O
"    O
,    O
"    O
Hypericum    O
olympicum    O
"    O
,    O
"    O
Hypericum    B-Antidepressant102718811
perforatum    I-Antidepressant102718811
"    O
,    O
"    O
Hypericum    O
rhodoppeum    O
"    O
and    O
"    O
Hypericum    O
tetrapterum    O
"    O
.    O

Notable    O
ones    O
include    O
Dalmatian    O
toadflax    O
,    O
spotted    O
knapweed    O
,    O
leafy    O
spurge    O
,    O
St.    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
,    O
and    O
sulfur    O
cinquefoil    O
.    O

The    O
list    O
of    O
plant    O
species    O
totals    O
471    O
and    O
includes    O
plants    O
such    O
as    O
wild    O
sarsaparilla    O
,    O
green    O
and    O
white    O
trilliums    O
,    O
wild    O
ginger    O
,    O
wild    O
geranium    O
,    O
Virginia    O
bluebells    O
,    O
Canada    O
yew    O
,    O
arrowhead    O
,    O
wild    O
leek    O
,    O
asparagus    O
,    O
wild    O
yam    O
,    O
red    O
mulberry    O
,    O
wild    O
columbine    O
,    O
Canada    O
anemone    O
,    O
chokecherry    O
,    O
Virginia    O
creeper    O
and    O
St.    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
.    O

In    O
addition    O
,    O
the    O
herbal    O
supplement    O
St.    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
may    O
decrease    O
the    O
serum    O
levels    O
of    O
zileuton    O
.    O

Badge    O
:    O
pine    O
(    O
Scots    O
Fir    O
)    O
or    O
St    B-Antidepressant102718811
John's    I-Antidepressant102718811
wort    I-Antidepressant102718811
(    O
St.    O
Columba    O
's    O
flower    O
)    O

2C-T-4    B-Antidepressant102718811

Tedatioxetine    B-Antidepressant102718811
(    O
Lu    B-Antidepressant102718811
AA24530    I-Antidepressant102718811
)    O
is    O
an    O
antidepressant    O
that    O
was    O
discovered    O
by    O
scientists    O
at    O
Lundbeck    O
;    O
in    O
2007    O
Lundbeck    O
and    O
Takeda    O
entered    O
into    O
a    O
partnership    O
that    O
included    O
tedatioxetine    O
but    O
was    O
focused    O
on    O
another    O
,    O
more    O
advanced    O
Lundbeck    O
drug    O
candidate    O
,    O
vortioxetine    B-Antidepressant102718811
.    O

Fluperlapine    B-Antidepressant102718811

L-733,060    B-Antidepressant102718811

Honokiol    B-Antidepressant102718811
,    O
a    O
compound    O
derived    O
from    O
"    O
Magnolia    O
officinalis    O
"    O
,    O
can    O
induce    O
paraptosis    O
in    O
human    O
leukemia    O
cells    O
.    O

Magnolol    O
,    O
honokiol    B-Antidepressant102718811
,    O
and    O
3,5′-diallyl-2′-hydroxy-4-methoxybiphenyl    O
exhibited    O
significant    O
activity    O
against    O
Gram    O
-    O
positive    O
and    O
acid    O
-    O
fast    O
bacteria    O
and    O
fungi    O
.    O

Pharmacology    B-Antidepressant102718811
of    I-Antidepressant102718811
antidepressants    I-Antidepressant102718811

Amitriptyline/perphenazine    B-Antidepressant102718811
(    O
Duo-Vil    B-Antidepressant102718811
,    O
Etrafon    B-Antidepressant102718811
,    O
Triavil    B-Antidepressant102718811
,    O
Triptafen    B-Antidepressant102718811
)    O
is    O
a    O
formulation    O
that    O
contains    O
the    O
tricyclic    O
antidepressant    O
amitriptyline    O
and    O
the    O
medium    O
-    O
potency    O
typical    O
(    O
first    O
-    O
generation    O
)    O
antipsychotic    O
,    O
perphenazine    O
.    O

As    O
of    O
2013    O
,    O
the    O
10    O
most    O
prescribed    O
psychiatric    O
drugs    O
by    O
number    O
of    O
prescriptions    O
were    O
alprazolam    O
,    O
sertraline    O
,    O
citalopram    B-Antidepressant102718811
,    O
fluoxetine    O
,    O
lorazepam    O
,    O
trazodone    O
,    O
escitalopram    B-Antidepressant102718811
,    O
duloxetine    O
,    O
bupropion    B-Antidepressant102718811
XL    I-Antidepressant102718811
,    O
and    O
venlafaxine    B-Antidepressant102718811
XR    I-Antidepressant102718811
.    O

Citalopram    B-Antidepressant102718811
(    O
Celexa    O
)    O
,    O
SSRI    O

Selective    O
serotonin    O
reuptake    O
inhibitors    O
(    O
SSRIs    O
)    O
,    O
such    O
as    O
sertraline    O
(    O
Zoloft    O
,    O
Lustral    O
)    O
,    O
escitalopram    B-Antidepressant102718811
(    O
Lexapro    O
,    O
Cipralex    O
)    O
,    O
fluoxetine    O
(    O
Prozac    O
)    O
,    O
paroxetine    O
(    O
Seroxat    O
)    O
,    O
and    O
citalopram    B-Antidepressant102718811
,    O
are    O
the    O
primary    O
medications    O
considered    O
,    O
due    O
to    O
their    O
relatively    O
mild    O
side    O
effects    O
and    O
broad    O
effect    O
on    O
the    O
symptoms    O
of    O
depression    O
and    O
anxiety    O
,    O
as    O
well    O
as    O
reduced    O
risk    O
in    O
overdose    O
,    O
compared    O
to    O
their    O
older    O
tricyclic    O
alternatives    O
.    O

Citalopram    B-Antidepressant102718811

Patients    O
taking    O
the    O
selective    O
serotonin    O
reuptake    O
inhibitors    O
(    O
SSRIs    O
)    O
Paxil    O
(    O
paroxetine    O
HCl    O
)    O
or    O
Celexa    O
(    O
citalopram    B-Antidepressant102718811
)    O
have    O
been    O
observed    O
yawning    O
more    O
often    O
.    O

Pharmacological    O
interventions    O
include    O
the    O
use    O
of    O
SSRIs    O
,    O
such    O
as    O
fluvoxamine    O
,    O
citalopram    B-Antidepressant102718811
,    O
escitalopram    B-Antidepressant102718811
,    O
and    O
naltrexone    O

Many    O
other    O
SSRI    O
antidepressants    O
are    O
fluorinated    O
organics    O
,    O
including    O
Celexa    B-Antidepressant102718811
,    O
Luvox    O
,    O
and    O
Lexapro    B-Antidepressant102718811
.    O

One    O
small    O
study    O
of    O
patients    O
with    O
excoriation    O
disorder    O
treated    O
with    O
citalopram    B-Antidepressant102718811
,    O
another    O
SSRI    O
,    O
showed    O
that    O
those    O
that    O
took    O
the    O
drug    O
significantly    O
reduced    O
their    O
scores    O
on    O
the    O
Yale    O
-    O
Brown    O
Obsessive    O
Compulsive    O
Scale    O
compared    O
to    O
placebo    O
,    O
but    O
that    O
there    O
was    O
no    O
significant    O
decrease    O
on    O
the    O
visual    O
-    O
analog    O
scale    O
of    O
picking    O
behavior    O
.    O

These    O
medicines    O
included    O
the    O
antidepressants    O
Citalopram    B-Antidepressant102718811
and    O
Duloxetine    O
,    O
as    O
well    O
as    O
the    O
antitussive    O
Dextromethorphan    O
and    O
the    O
antihistamines    O
Diphenhydramine    O
and    O
Chlorpheniramine    O
.    O

Mirtazapine    O
is    O
considered    O
to    O
be    O
relatively    O
safe    O
in    O
the    O
event    O
of    O
an    O
overdose    O
,    O
although    O
it    O
is    O
considered    O
slightly    O
more    O
toxic    O
in    O
overdose    O
than    O
most    O
of    O
the    O
SSRIs    O
(    O
except    O
citalopram    B-Antidepressant102718811
)    O
.    O

Citalopram    B-Antidepressant102718811

It    O
was    O
shown    O
to    O
completely    O
reverse    O
the    O
autoreceptor    O
-    O
mediated    O
inhibition    O
of    O
serotonin    O
release    O
induced    O
by    O
the    O
administration    O
of    O
selective    O
serotonin    O
reuptake    O
inhibitors    O
like    O
citalopram    B-Antidepressant102718811
in    O
rodent    O
studies    O
.    O

In    O
level    O
one    O
,    O
patients    O
received    O
the    O
selective    O
serotonin    O
reuptake    O
inhibitor    O
(    O
SSRI    O
)    O
citalopram    B-Antidepressant102718811
for    O
up    O
to    O
14    O
weeks    O
,    O
with    O
adjustment    O
of    O
the    O
dose    O
being    O
managed    O
by    O
their    O
own    O
physicians    O
.    O

Citalopram    B-Antidepressant102718811

melitracen    B-Antidepressant102718811
(    O
INN    O
)    O

Melitracen    B-Antidepressant102718811

Following    O
the    O
ban    O
,    O
other    O
phenethylamines    O
were    O
sold    O
in    O
place    O
of    O
2C    O
-    O
B    O
until    O
the    O
Netherlands    O
became    O
the    O
first    O
country    O
in    O
the    O
world    O
to    O
ban    O
2C    O
-    O
I    O
,    O
2C-T-2    B-Antidepressant102718811
and    O
2C-T-7    B-Antidepressant102718811
alongside    O
2C    O
-    O
B.    O

In    O
Australia    O
,    O
2C-T-2    B-Antidepressant102718811
and    O
2C    O
-    O
T-7    O
are    O
covered    O
by    O
the    O
country    O
's    O
analogue    O
drug    O
laws    O
.    O

2C-T-2    B-Antidepressant102718811

Radafaxine    B-Antidepressant102718811
(    O
GW-353,162    O
)    O

Radafaxine    B-Antidepressant102718811

Saredutant    B-Antidepressant102718811
(    O
SR-48,968    B-Antidepressant102718811
)    O
is    O
a    O
drug    O
that    O
acts    O
as    O
a    O
NK2    O
receptor    O
antagonist    O
.    O

Many    O
species    O
formerly    O
placed    O
in    O
"    O
Mesembryanthemum    O
"    O
,    O
such    O
as    O
"    O
Dorotheanthus    O
bellidiformis    O
"    O
,    O
"    O
Carpobrotus    O
"    O
spp    O
.    O
and    O
"    O
Sceletium    B-Antidepressant102718811
"    O
spp    O
.    O
have    O
since    O
been    O
moved    O
into    O
other    O
genera    O
.    O

"    O
Sceletium    B-Antidepressant102718811
tortuosum    I-Antidepressant102718811
"    O
,    O
a    O
Southern    O
African    O
succulent    O
with    O
psychoactive    O
properties    O

Nomifensine    B-Antidepressant102718811

Diclofensine    O
is    O
chemically    O
a    O
tetrahydroisoquinoline    O
(    O
THIQ    O
)    O
derivative    O
,    O
as    O
is    O
nomifensine    B-Antidepressant102718811
.    O

It    O
was    O
concluded    O
that    O
,    O
at    O
least    O
in    O
the    O
models    O
employed    O
,    O
the    O
in    O
vitro    O
profile    O
of    O
fencamfamin    O
is    O
more    O
similar    O
to    O
that    O
of    O
nomifensine    B-Antidepressant102718811
,    O
a    O
reportedly    O
pure    O
uptake    O
inhibitor    O
,    O
than    O
to    O
d    O
-    O
amphetamine    O
.    O

The    O
status    O
of    O
antidepressants    B-Antidepressant102718811
in    I-Antidepressant102718811
Japan    I-Antidepressant102718811
that    O
are    O
approved    O
by    O
the    O
Japanese    O
Authorities    O
is    O
an    O
issue    O
that    O
needs    O
to    O
be    O
followed    O
as    O
it    O
has    O
traditionally    O
lagged    O
far    O
behind    O
the    O
West    O
.    O

2C-T-7    B-Antidepressant102718811
,    O
a    O
hallucinogenic    O
phenethylamine    O

In    O
the    O
United    O
States    O
,    O
2C    O
-    O
T-19    O
is    O
not    O
illegal    O
,    O
but    O
possession    O
and    O
sales    O
of    O
2C    O
-    O
T-19    O
could    O
be    O
prosecuted    O
under    O
the    O
Federal    O
Analog    O
Act    O
because    O
of    O
its    O
structural    O
similarities    O
to    O
2C-T-7    B-Antidepressant102718811
.    O

2C-T-7    B-Antidepressant102718811

Octriptyline    B-Antidepressant102718811

Tetracyclic    B-Antidepressant102718811
antidepressant    I-Antidepressant102718811
mirtazapine    B-Antidepressant102718811
and    O
mianserin    O
are    O
also    O
potent    O
α    O
antagonists    O
with    O
mirtazapine    O
being    O
more    O
selective    O
for    O
α2    O
subtype    O
(    O
~30-fold    O
selective    O
over    O
α1    O
)    O
than    O
mianserin    O
(    O
~17-fold    O
)    O
.    O

As    O
a    O
MAO    O
inhibitor    O
,    O
safinamide    O
can    O
theoretically    O
cause    O
hypertensive    O
crises    O
,    O
serotonin    O
syndrome    O
and    O
other    O
severe    O
side    O
effects    O
when    O
combined    O
with    O
other    O
MAO    O
inhibitors    O
or    O
with    O
drugs    O
that    O
are    O
known    O
to    O
interact    O
with    O
MAO    O
inhibitors    O
,    O
such    O
as    O
pethidine    O
,    O
dextromethorphan    O
,    O
serotonin–noradrenaline    B-Antidepressant102718811
reuptake    I-Antidepressant102718811
inhibitor    I-Antidepressant102718811
(    O
SNRIs    O
)    O
,    O
tricyclic    O
and    O
tetracyclic    B-Antidepressant102718811
antidepressant    I-Antidepressant102718811
.    O

Chemically    O
,    O
mirtazapine    O
is    O
a    O
tetracyclic    B-Antidepressant102718811
antidepressant    I-Antidepressant102718811
(    O
TeCA    O
)    O
,    O
with    O
four    O
interconnected    O
rings    O
of    O
atoms    O
,    O
and    O
is    O
a    O
relative    O
of    O
the    O
TeCA    O
mianserin    O
(    O
Tolvon    O
)    O
.    O

On    O
the    O
psychiatric    O
front    O
researchers    O
at    O
Newhouse    O
supported    O
the    O
development    O
of    O
mirtazepine    B-Antidepressant102718811
,    O
a    O
novel    O
tetracyclic    B-Antidepressant102718811
anti    O
-    O
depressant    O
which    O
has    O
become    O
widely    O
prescribed    O
throughout    O
the    O
world    O
.    O

They    O
are    O
named    O
after    O
their    O
chemical    O
structure    O
,    O
which    O
contains    O
three    O
rings    O
of    O
atoms    O
,    O
and    O
are    O
closely    O
related    O
to    O
the    O
tetracyclic    B-Antidepressant102718811
antidepressant    I-Antidepressant102718811
(    O
TeCAs    O
)    O
,    O
which    O
contain    O
four    O
rings    O
of    O
atoms    O
.    O

Porfimer    O
is    O
Haematoporphyrin    B-Antidepressant102718811
Derivative    O
(    O
HpD    O
)    O
(    O
See    O
PDT    O
)    O
.    O

lemongrass    B-Antidepressant102718811
(    O
"    O
Cymbopogon    O
citratus    O
"    O
)    O

"    O
Bambusoideae    O
"    O
-    O
"    O
Imperata    O
brasiliensis    O
"    O
-    O
"    O
Melinis    O
minutiflora    O
"    O
-    O
"    O
Cymbopogon    B-Antidepressant102718811
citratus    I-Antidepressant102718811
"    O
.    O

αMT    B-Antidepressant102718811

α-Methyltryptamine    B-Antidepressant102718811
αMT    O
(    O
Indopan    O
)    O
–    O
non    O
-    O
selective    O
serotonin    O
receptor    O
agonist    O
,    O
serotonin    O
–    O
norepinephrine    O
–    O
dopamine    O
releasing    O
agent    O
(    O
SNDRA    O
)    O
,    O
and    O
weak    O
RIMA    O

On    O
April    O
4    O
,    O
2003    O
,    O
the    O
United    O
States    O
DEA    O
added    O
both    O
5-MeO    O
-    O
DiPT    O
and    O
AMT    B-Antidepressant102718811
to    O
Schedule    O
I    O
of    O
the    O
Controlled    O
Substances    O
Act    O
under    O
"    O
emergency    O
scheduling    O
"    O
procedures    O
.    O

AMT    B-Antidepressant102718811

5-Hydroxy    O
-    O
alpha    O
-    O
methyltryptamine    O
is    O
not    O
scheduled    O
at    O
the    O
federal    O
level    O
in    O
the    O
United    O
States    O
,    O
but    O
it    O
could    O
be    O
considered    O
an    O
analog    O
of    O
alpha-methyltryptamine    B-Antidepressant102718811
(    O
AMT    O
)    O
,    O
in    O
which    O
case    O
,    O
purchase    O
,    O
sales    O
,    O
or    O
possession    O
could    O
be    O
prosecuted    O
under    O
the    O
Federal    O
Analog    O
Act    O
.    O


